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ABSTRACT
The Impact of Processing on the Content and Composition of Bovine Milk Extracellular Vesicles
by Anna Paula Colella
Bovine milk (BM)-based formula is an alternative for many newborns who do not
consume human milk. BM contains extracellular vesicles (EVs), bioactive compounds involved
in intercellular communication which regulate critical developmental processes in early life. It
was hypothesized that the industrial processing of raw BM affected the content and composition
of BM EVs. It is critical to understand how industrial processing affects EVs in BM since
changes in the content and composition may attenuate the functions of these bioactive
compounds in human health. EVs from raw BM were isolated and characterized in accordance
with the Minimal Information for Studies of EVs (MISEV) criteria. Raw milk was subjected to
homogenization and pasteurization (ultra-high-temperature, high-temperature short-time)
treatments individually and in combination. Processed BM EVs were assessed for concentration,
size, and protein and miRNA concentrations. All industrial processing treatments caused
significant losses of EVs, when compared to the raw BM reference. The protein and miRNA
concentrations adjusted for EV number were significantly higher only in the preheated
homogenization group, possibly indicating that the remaining EVs had the highest protein and
miRNA densities across all treatments. Industrial heat and homogenization treatments may select
for specific populations of EVs, alter EV composition within the BM matrix, or affect the
integrity of the EV membrane and macromolecular content within. While current efforts on
infant formula development are focused on mimicking human milk, the possible loss of raw milk
EVs during processing had not yet been addressed. This new foundational knowledge may
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contribute to future research on the preservation of EVs in processed dairy products, including
infant formula, and narrowing the compositional gap with human milk.

Keywords: Cow’s Milk, Dairy, Exosome, Homogenization, Pasteurization, UHT, HTST
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1

INTRODUCTION
Understanding the impact of processing on bovine milk extracellular vesicles (EVs)

addresses the 2020 priorities for USDA’s Food and Human Health, program area Novel Foods
and Innovative Manufacturing Technologies, priority code A1364 (USDA, 2020). This research
investigated the resilience of EVs in raw milk processed in a pilot plant simulating a large-scale
process. The effects of homogenization and pasteurization on bovine milk EVs were evaluated
through the characterization of processing effects on the content and composition of EVs. The
results obtained provide a starting point for the development of innovative manufacturing
technology for the improvement of dairy derivatives with a focus on the preservation of EVs
(USDA, 2020).
Mimicking the valuable nutritional components of bovine milk may be a challenge on the
development of plant-based beverages for adults, but of even greater importance is reproducing
human milk on infant formulas. Although the American Academy of Pediatrics recommends
children to be exclusively breastfed for the first six months of life, only about 25 % of parents in
the USA follow this recommendation (AAP, 2012; CDC, 2017b). Commercial formulas are the
only alternative for feeding newborns who cannot be fed human milk. Some infants may not be
fed human milk in accordance with recommendations because of insufficient production of
human milk, limited support, convenience, or more serious maternal or infant conditions such as
birth defects and illnesses. Of children consuming formula or regular milk as alternatives to
human milk, 69.4 % are fed bovine milk-based formula, 12.4 % consume soy-based formula,
while smaller percentages consumed specialty formula (7.5 %), gentle/lactose-reduced formula
(4.4 %), and regular milk (6.3 %) (Rossen, Simon, & Herrick, 2016). The challenge in formula
development lies not only on mimicking the macronutrient and micronutrients present in breast
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milk, but also on the large-scale manufacturing or protection, during processing, of bioactive
components such as extracellular vesicles (EVs). Commercial bovine milk-based infant formula
is a highly processed product derived from raw milk, which is processed through treatments that
include homogenization, heat treatments, evaporation, and spray-drying.
EVs are nanoparticles released to the extracellular environment by most living cells. EV
content (cargos) refers to the molecules present in the interior of these nanovesicles, including
proteins, lipids, non-coding RNA, and mRNA. The composition of EVs refers to the
phospholipid bilayer enclosing the nanoparticles, as well as its’ components (cell surface
proteins) (Akuma, Okagu, & Udenigwe, 2019; Zempleni et al., 2016). EVs are involved in
intercellular communication, and it has been documented that microRNA (miRNA) contained in
human milk EVs can regulate infant immunity, growth, and development, while also
contributing to metabolic processes (Alsaweed, Lai, Hartmann, Geddes, & Kakulas, 2016; de la
Torre Gomez, V. Goreham, J. Bech Serra, Nann, & Kussmann, 2018). MicroRNA are short, noncoding RNA that contain ~22 nucleotides and suppress translation mRNA or cause degradation
of target RNA. Evidence suggests that miRNA are involved in a wide range of developmental
processes, including fat metabolism, muscle differentiation, and cancer (Mattick & Makunin,
2006). The physiologic function of bovine milk EVs in infant nutrition and their inclusion in
infant formula products is yet to be further explored. Although bovine milk has some similarity
with human milk in miRNA content because of the common mammalian nature, bovine milkbased formula does not contain a comparable amount of mature miRNA species as in human
milk fractions, possibly as a result of the formula manufacturing process. Furthermore, the plant
nature of soy-based formula makes it poorly correlate with the human milk miRNA profile
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(Alsaweed et al., 2016). The poor miRNA profile in formulas when compared to human milk
indicates a possibly insufficient delivery of these compounds to the developing infant.
Zhou et al. (2019) found that bovine milk RNA and exosomes, a type of EV, alter the gut
microbiome composition in mice. However, the miRNA content of the bovine milk that is part of
humans’ diet decreases during processing and storage (Howard et al., 2015). Interestingly, most
of the miRNA in bovine milk is encapsulated in membrane vesicles that confers protection
against degradation (Baier, Nguyen, Xie, Wood, & Zempleni, 2014). When miRNA resilience
was tested, results indicated that endogenous miRNA concentrations decreased by 50 % when
homogenized. This reduction may be caused by the disruption of exosome membranes during
homogenization. Degradation of miRNA was also noted during fermentation, pasteurization and
processing of dairy products (Howard et al., 2015). The exosomal membrane is composed of a
lipid bilayer, and further research is needed to elucidate the composition of exosomes secreted by
different cells for an understanding of its function and variability, especially during processing.
This study characterized bovine milk EVs in raw and in processed milk. The data collected
indicated that the concentration of EVs changed with processing, and how their content and
composition were affected. These results can serve future studies on the improvement of dairy
processing, especially for the manufacture of bovine milk-based infant formula.
The long-term goal of this study is to provide suggestions of process improvement for
future development in commercial infant formulas regarding the addition of bioactive
compounds or the modification of processing treatments to preserve them. This study
characterized extracellular vesicles before and after processing, adding relevant information on
bioactive molecules to what is already known about the macro and micronutrient profile, leading
to infant formula with increasing similarity to human milk. Maga et al. (2012) demonstrated that
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manipulating one single bioactive diet component might be beneficial for the consumer. For
instance, the fortification of bovine milk with lysozyme, an enzyme present in human milk,
resulted in improved gut health due to its antimicrobial properties. Evidence suggests that the
miRNA in human milk EVs are similar to those present in bovine milk EVs, and thus there may
be an interest on preserving or fortifying formulations with these compounds (X. Chen et al.,
2010; Herwijnen et al., 2018). Further investigations on the composition and function of bovine
milk EVs may allow for a better understanding of the possibilities and benefits of utilizing
bioactive molecules in milk formulations.
This study is innovative because it can improve infant formulas by shifting the focus
from the addition of vitamins and nutrients to the processing steps that might disrupt the valuable
bioactive molecules present in raw milk. Although the content and composition of bovine milk
EVs has been generally characterized, variability across breeds and lactation periods remains to
be further detailed. Furthermore, how EVs may be affected by processing treatments has not
been thoroughly characterized. This investigation aims to expand on this knowledge, by
evaluating and comparing the content and composition of bovine milk EVs in raw and processed
milk. The quantity and size of EVs, and total concentration of EV proteins and miRNA were
described and compared between the milk samples. Since human donor milk is usually
pasteurized in milk banks, results from our study may help improve its quality, while ensuring
safety for consumption. This study may contribute to narrowing the compositional gap between
human milk and infant formula, ensuring better health outcomes for newborns that consume
formula.
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2
2.1

REVIEW OF LITERATURE
Overview of Extracellular Vesicles
Extracellular vesicles (EVs) are organelles released to the extracellular space by most

living cells (Carolina de la Torre, Renee, Joan, Thomas, & Martin, 2018; Mathivanan, Ji, &
Simpson, 2010). EVs harbor compounds such as proteins, lipids, non-coding RNA (ncRNA),
mRNA, and are enclosed by a phospholipid bilayer, as illustrated in Figure 2-1 (Akuma et al.,
2019; Zempleni et al., 2016). In 2013, the Nobel Prize in Physiology or Medicine was awarded
to Ames E. Rothman, Randy W. Schekman and Thomas C. Südhof for their work on
extracellular vesicles and for describing the role of EVs in regulating a key function: the
transport and delivery of cellular cargo (Nobel Media, 2013). EVs have been widely researched
for their involvement in cellular activity not only in the human body, but also when being
transferred between species, especially when derived from dietary sources such as milk, fruits
and vegetables (Mu et al., 2014; Pieters et al., 2015; Pérez-Bermúdez, Blesa, Soriano, &
Marcilla, 2017). Besides functioning in intercellular communication, EVs are promising
biomarkers for disease diagnostics and treatment, including cancer and neurodegeneration (de la
Torre Gomez et al., 2018). The three main categories of EVs are exosomes, apoptotic bodies, and
shedding microvesicles (Mathivanan et al., 2010). These categories are related to their origin
within the cell, the vesicle size, function, and biogenesis (Carolina de la Torre et al., 2018). EVs
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are present in the extracellular environment in the culture supernatant of cells and in
physiological fluids (Niel, Porto-Carreiro, Simoes, & Raposo, 2006).

Figure 2-1 The composition of EVs, simplified. Adapted from de Jong et al. (2019)
2.1.1

The types and composition of extracellular vesicles
Shedding microvesicles, or ectosomes, have a diameter between 50 and 1000 nm and are

released from the plasma membrane through a regulated budding mechanism (Cocucci,
Racchetti, & Meldolesi, 2009; de Jong et al., 2019). These vesicles were first described by Stein
& Luzio (1991), who observed the shedding of right-side-out plasma membrane derived vesicles
containing intracellular components such as proteins, lipids and mRNA. Shedding vesicles are
involved in coagulation, inflammation, and tumorigenesis. Besides their role in pathogenesis, the
treatment of diseases also represents a promising application of the specificity of these vesicles
in medicine. The mechanisms that enable some of these functions are related to their molecular
specificity, to their interaction with target cells through signaling and delivery of genetic
material, which is a common attribute to other types of EVs as well (Cocucci et al., 2009).
Apoptotic bodies (ApoBDs) have a diameter ranging from 50 to 500 nm (Mathivanan et
al., 2010). These ApoBDs are released during the last stages of cellular apoptosis (programmed
cell death), and help promote the removal of cell debris, setting off phagocytosis and ensuring
the maintenance of healthy tissues (Atkin-Smith & Poon, 2017; Hina, Gregor, & Suresh, 2016).
6

Exosomes, whose size can vary from 40 to 100 nm, are the most promising type of EVs
(Raposo & Stoorvogel, 2013). Multivesicular bodies are formed inside the cell and, once fused
with the membrane, are released to the extracellular environment and named exosomes (de Jong
et al., 2019). The cargo in exosomes consists of various species of RNA, endosome-associated
proteins and fatty acids (Raposo & Stoorvogel, 2013). There is growing interest in the use of
exosomes to diagnose and treat diseases, especially for their ability to carry cargos sorted
through internal mechanisms, and for delivering intercellular communication. Exosomes released
from cancer cells contribute to metastasis through the delivery of cancerous cargo to healthy
cells. The EV membrane surface interacts with receptors on the cell surface, which explains the
potential for drug delivery and disease treatment (Abels & Breakefield, 2016; Carolina de la
Torre et al., 2018). When compared to other EVs, exosomes have displayed the most stability,
and would therefore protect their contents from degradation (Akuma et al., 2019).
Interestingly, no consensus has been achieved on specific markers of each EV subtype, so
classification of a vesicle to a specific biogenesis pathway remains inconsistent, unless live
imaging techniques allow for visualization. For this reason, the ISEV suggests the use of the
general term EV when referring to particles released by the cell which are limited by a
phospholipid bilayer, do not contain a live functioning nucleus, and cannot replicate (Théry et
al., 2018). Although some literature review herein presented differentiates between these
subtypes, the recommendation of naming these particles EVs and using operational
classifications referring to their physical characteristics was followed on presenting the findings
of this research. Specifically, EVs with a diameter smaller than 200 nm were denominated
smallEVs (sEVs), while EVs with a diameter greater than 200 nm were defined as largeEVs
(lEVs).
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2.1.2

Extracellular vesicles have diverse functions
Extracellular vesicles have many different functions, not only in regulating normal

functioning of organisms, but also in pathological pathways related to tumor progression (de la
Torre Gomez et al., 2018). Initially, EVs were believed to have the main function of eliminating
excessive proteins and debris from the cell, notably through apoptotic bodies. Recently, the
primary role of EVs for intercellular communication, with other complementary functions, was
suggested. Exosomes may regulate lactation, have immunomodulatory properties, and participate
in the expansion and progression of diseases, stem cell maintenance, and tissue homeostasis
(Rashed et al., 2017). The oxidized phospholipids present in microvesicles are a response to
oxidative stress and are implicated in inflammation and coagulation, often indicators of
pathogenesis such as atherosclerosis, thrombosis and arthritis (VanWijk, VanBavel, Sturk, &
Nieuwland, 2003). Apoptotic bodies are mainly involved in the removal of cell debris (Battistelli
& Falcieri, 2020). EVs being released by mammalian cell types and exosome-like particles found
in plants are a part of the human diet, and it has been suggested that these vesicles may confer
benefits to a consumer (Hirohisa Izumi et al., 2015; Kosaka, Izumi, Sekine, & Ochiya, 2010; Mu
et al., 2014). Although EVs have been attributed many roles, the function of dietary EVs remains
to be further explored. Some milk exosome miRNA have been evaluated within and among
species, but the biological function of most miRNA remains unknown (Hirohisa Izumi et al.,
2015).
2.1.3

Extracellular vesicles as part of the human diet
Bioactive compounds are chemicals derived from plants and certain foods that play roles

in the human body and are being studied in the prevention of diseases and for promoting good
health (NCI, 2020). Exosomal miRNA are transferred to humans through food, alter gene
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expression, and result in diverse benefits to human health (Baier et al., 2014). EVs can therefore
be classified as bioactive compounds. In addition to EVs derived from excretion by mammalian
cells, EVs and exosome-like particles are also found in foods such as carrots, ginger, grapefruit,
grapes (Mu et al., 2014; Pérez-Bermúdez et al., 2017), and sunflower seeds (Regente, Pinedo,
Elizalde, & de la Canal, 2012). The structure and size of these plant-derived exosomes are
similar to the mammalian-derived exosomes, and both are composed of proteins, lipids and
genetic material, but the biogenesis of these plant vesicles is still not clear (Akuma et al., 2019).
Edible plant derived exosome-like nanoparticles (EPDENs) were isolated from root juice using a
technique similar to that used for mammalian exosomes. The total concentration of EPDENs
obtained from 100 g of grapefruit, grapes, ginger, and carrot was similar (ranging between 330
and 450 mg of EPDENs/100 g of edible plant), and the concentration of RNA extracted from the
same EDPENs varied from 2.5 to 15.5 RNA µg/100 mg of EPDENs. EPDENs derived from
ginger maintain intestinal immune cell homeostasis in gut through the induction of pro- and antiinflammatory cytokines (Mu et al., 2014). Further studies may support the idea that ingesting
EPDENs from a variety of plant sources is beneficial for human gut health. Exosome-like
particles were also isolated from sunflower seeds and identified as a possible mechanism for
intercellular communication between plant eukaryotic cell types, notably for protein secretion
(Regente et al., 2012). The particles were isolated from sunflower extracellular fluid through
ultracentrifugation, showed a diameter of 50-200 nm, and a lipid bilayer similar to that of
animal-derived exosomes (Regente et al., 2009).
EVs from certain foods have been suggested as effective therapeutic agent carriers.
Exosomes can be loaded with cargos and are expected to be biocompatible, safe, and bind to
specific targets due to their unique surface compositions (Akuma et al., 2019). Compared to
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crude ginger extracts, which are used in the treatment of diverse inflammatory conditions, ginger
EPDENs are taken up preferentially by intestinal macrophages or monocytes and thus may have
a better therapeutic effect (Mu et al., 2014). An ongoing clinical trial started in 2012 is
evaluating the anti-inflammatory effect of grape exosomes in chemoradiation patients,
specifically investigating the suppression of oral mucositis, a common complication of cancer
treatments (Redman, 2012). Mammalian exosomes have also been shown to successfully
encapsulate bioactive compounds and ensure target specificity (D. Sun et al., 2010; Zhuang et
al., 2011). The development of these applications from food EVs depends on an understanding of
a wide array of these vesicles, their sources, cargos, distribution patterns, uptake in the human
body, and possible related health impacts.
2.1.4

Extracellular vesicles derived from mammalian cells
Almost every mammalian cell type releases EVs (Carolina de la Torre et al., 2018). EVs

are found throughout a mammalian’s body in fluids such as the urine, semen, plasma, milk, tears,
sweat, and saliva (Lawson, Vicencio, Yellon, & Davidson, 2016). Seminal plasma was found to
be the richest source of EVs in porcine species, followed by blood plasma and cerebrospinal
fluid (Skalnikova et al., 2019). The inter- and intraspecies transfer of EVs is common, especially
of those derived from mammalian cells. An example of intraspecies transfer happens during the
breastfeeding of infants. Interspecies transfer occurs when humans consume products derived
from other mammals such as cow (X. Chen et al., 2010), buffalo (Baddela, Nayan, Rani, Onteru,
& Singh, 2016), goat (Y. Sun, Wang, Sun, & Guo, 2019), and dromedary milk (Yassin, Abdel
Hamid, Farid, Amer, & Warda, 2016). It was suggested that exosomes transferred intraspecies
are more bioavailable than interspecies (Manca et al., 2018). Breastfeeding plays an essential
role on the maturation of an adult-like microbiota in infants, suggesting that the exosomes in
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human milk, as well as its regulatory cargos such as miRNA, may also be related to life-long
effects on metabolic and immune health (Bäckhed et al., 2015; Kosaka et al., 2010). In fact, it
has been shown that piglets fed human milk showed better gut and systemic immune responses
than piglets fed commercial formula, and these positive outcomes may be related to the
influences of human milk on the intestinal microbiota composition of piglets (Miklavcic et al.,
2018).
The variations in EV content and composition across bovine milks is unknown, although
evidence suggests that bovine miRNA profiles, including exosomal miRNA, differ among
cattle’s breeds and between colostrum and mature milk (X. Chen et al., 2010; H. Izumi et al.,
2012; Özdemir, 2020). Cow’s milk miRNA and mRNA can resist degradation to low pH and
RNase treatment, suggesting that the genetic material is protected by a membrane that keeps
miRNA and mRNA intact when passing the gastrointestinal tract and before absorption in the
intestine (H. Izumi et al., 2012). Similarly, it has been confirmed that cow’s milk miRNA
withstand the harsh conditions of digestion (low pH, digestive enzymes and secretions) on a
model gastrointestinal tract (Benmoussa et al., 2016).
2.2

Human milk contains extracellular vesicles
Human milk is a complete source of bioactive compounds, micronutrients, and

macronutrients, especially for term infants. Infant formula manufacturers are facing the
challenge of adding bioactive ingredients to infant formula in an attempt to mimic components of
human milk. This includes maternal antibodies, immunoregulatory proteins, and human milk
oligosaccharides (HMOs), which play essential roles in the cognitive, immunological, and
healthy development of an infant (Caspi et al., 2007; Ruiz-Palacios, Cervantes, Ramos, ChávezMunguia, & Newburg, 2003). This challenge is further heightened by the individual variations of
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the milk profile in mothers, the shifts in milk composition for each lactation period, and the
discoveries of new components in human milk (Petherick, 2010). Human milk also contains
exosomes filled with essential cargo for the infant nutrition and health (Kosaka et al., 2010). Like
exosomes released by other living species, human milk exosomes contain lipids, proteins, and
genetic material (Zempleni et al., 2016). The roles of human milk EVs include regulating
immune response and inflammation (Carolina de la Torre et al., 2018). The composition of
exosomes in human milk changes during different periods of lactation. Early milk from mothers
at week 1 of lactation is more abundant in exosomes and has a significantly higher exosomal
protein content than mature milk (2 months postpartum). These variations can directly impact the
infant health. The phenotype of exosomes also varies with the mother’s lifestyle: it has been
shown that children breastfed by mothers following an anthroposophic lifestyle are less likely to
develop allergies (Torregrosa Paredes et al., 2014).
In human milk, extracellular vesicles harbor cargos that may not only serve as fingerprint
of the mother’s health, but also of possible outcomes to the health of the infant being breastfed.
Liao, Du, Li & Lönnerdal (2017) tested the resilience of human milk exosomes to in vitro
simulated gastric and pancreatic digestion of infants, finding these vesicles to be largely stable to
the harsh conditions (low pH and RNase treatment) across the lactation period tested (from
infants 1.5 to 8 months old). Most of the miRNA content in human milk is protected inside
exosomes (Q. Zhou et al., 2012). Exosomes serve as biomarkers of disease such as cancer and
neurodegenerative conditions (Carolina de la Torre et al., 2018). High-fat diets significantly
impacted (up- and downregulating) the content of miRNA present in milk in lactating mice (Y.
Chen et al., 2017). Cumulatively, this evidence suggests that miRNA could be a tool for
monitoring a mother’s health status and dietary patterns, which could directly impact the
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breastfeeding infant. Experimental evidence for the internalization of human milk exosomes to
the nucleus of human intestinal epithelial crypt-like cells was noted (Liao et al., 2017). Although
the role of exosome cargos in infant nutrition is yet to be studied in detail, human milk miRNA
are involved in diverse biological functions in infants, such as immunity, growth and
development, cell proliferation and apoptosis, lung epithelial progenitor cell differentiation, and
epithelial-to-mesenchymal transition (Alsaweed et al., 2016). Hence, understanding the
importance of EV content and composition to infant health may further contribute to
improvements in infant formula development.
2.3

Bovine milk extracellular vesicles influence human health
Bovine milk is a staple of many diets. Nutritionally, milk is considered a complete food

for adults because it provides many of the nutrients required daily by the human body such as
lipids, proteins, amino acids, vitamins, minerals, and bioactive compounds. Consuming bovine
milk in moderate amounts daily (up to 0.5 L) would supply humans with significant amounts of
these required nutrients (Haug, Høstmark, & Harstad, 2007). The EVs are one of the many
important bioactive compounds in bovine milk. An example of EV transfer between species is on
the consumption of dairy products by humans. The role of EVs in human health needs to
encompass a thorough analysis of the cargos in EVs and an understanding of its impacts in the
human body. The distribution patterns of milk exosomes administered to mice after labeling with
fluorophores or fluorescent fusion proteins has been analyzed. The route of bovine milk
exosomes fed to suckling mice was compared to that of endogenously labeled milk exosomes
from transgenic mice delivered within species. Results indicated that each different miRNA
cargo in bovine milk exosomes displays unique profiles of distribution when labeled,
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accumulating in the intestinal mucosa, spleen, liver, heart or brain, which might suggest greater
bioavailability of milk exosomes within than among species (Manca et al., 2018).
Raw bovine milk derived miRNA is stable at a pH of 2, in the presence of RNase, and at
37 ˚C (the human body temperature), suggesting that their cargo remains stable during human
digestion and supporting the theory that the majority of miRNA in milk are protected by the EV
membrane (H. Izumi et al., 2012). After consuming bovine milk, specific miRNA from this
species can be detected in human plasma (Shu, Chiang, Zempleni, & Cui, 2015). While the
intestinal transport mechanisms of bovine milk exosomes in humans is unclear, there is evidence
that the amount of milk miRNA absorbed by the human body is enough to alter human gene
expression. Furthermore, a regular dietary intake of miRNA may prevent aberrant gene
regulation. Mice fed a miRNA-depleted diet had significantly lower miR-29b concentrations on
their plasma and were not able to compensate for this dietary deficiency with endogenous
miRNA transcription (Baier et al., 2014). The bioavailability of miRNA is highly variable with
the miRNA species and the distribution pattern depends on the route of administration (in mice,
through suckling, oral gavage or intravenous administration). Milk exosome contents are
bioavailable and can circulate to the brain, liver, and spleen of mice – mainly across peripheral
tissues (Howard et al., 2015; Manca et al., 2018; Wolf, Baier, & Zempleni, 2015). Bovine milk
exosomes are taken up by endocytosis into human vascular endothelial cells (Kusuma et al.,
2016) and by human macrophages (Hirohisa Izumi et al., 2015).
In addition to miRNA, bovine milk EVs also contain other non-coding RNA (ncRNA)
such as transfer RNA (tRNA) and ribosomal RNA (rRNA), but the function of these molecules
in milk is still unknown (Zempleni et al., 2016). Non-coding RNA are genetic materials that do
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not code for proteins, and the biological functionality of most of them in humans remains unclear
(Palazzo & Lee, 2015).
Some concerns to human health raised from exosomes and their cargos include their role
as pathogens of diseases such as Parkinson’s, obesity, type 2 diabetes, osteoporosis, and common
cancers (Melnik & Schmitz, 2019). The rich miRNA content in human milk EVs is linked to an
essential programming of the postnatal physiological health of the infant. However, commercial
infant formula contains insufficient amounts of bovine milk miRNA, which would compromise
postnatal epigenetic programming, thus increasing the risk for the before-mentioned diseases. It
has been suggested that the genetic material in raw cow’s milk is abundant in miRNA with
epigenetic potential (miRNA that can induce long-term changes in gene expression), and is even
more abundant in dairy cows treated with hormones for increased lactation performance (C. B.
Melnik & G. Schmitz, 2017). The concern are exosome components such as oncogenic miRNA
(miR-148a, mir-21, miR-29b, miR-155), epithelial-mesenchymal transition-promoting
transforming growth factor-beta (TGF- β), neurotoxic proteins, viruses (Melnik & Schmitz,
2019). Melnik & Schmitz (2017) therefore suggest that milk should be removed from the human
food chain. In contrast, Pieters et al. (2015) suggested a beneficial role in the recipient’s immune
system through the presence of immunoregulatory miRNA and the same previously mentioned
TGF-β in the vesicles. TGF-β is a cytokine that participates in the differentiation of T cells into
proinflammatory cells, which can be beneficial for healthy subjects, although pathogenic for
individuals with active infections.
Bovine milk EVs contain a phospholipid bilayer membrane, which provides stability in
the human gastrointestinal tract and absorption in the intestine (H. Izumi et al., 2012), where they
start regulating a variety of metabolic pathways. The intestinal uptake of bovine milk exosomes
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can happen by endocytosis in humans and rats. When investigating different doses of bovine
milk exosomes and the influence of inhibitors and competitors on the absorption of the vesicles
in human colon carcinoma Caco-2 cells for humans and rat small intestinal IEC-6 cells, it was
found that the removal of surface proteins in both exosomes and cells and the treatment of Caco2 cells with carbohydrate competitors decreased the uptake of bovine milk exosomes. Wolf,
Baier, & Zempleni (2015) therefore indicate that the bioavailability of exosomes depends on
their surface composition, e.g. plant vesicles have a poor compatibility of glycoproteins with
mammalian intestinal cell receptors. Different macronutrients and micronutrients affect the
expression of miRNA and thus following this idea a diet can be designed to maximize the
expression of beneficial miRNA and minimize the activity of detrimental miRNA with a focus
on the treatment and prevention of diseases. This represents a new approach for personalized and
therapeutic human nutrition (García-Segura, Pérez-Andrade, & Miranda-Ríos, 2013). This
approach can start very early in the food supply chain since the diet of dairy cows can impact the
physiological state of the animals and the miRNA profiling present in bovine milk as well.
Support for this idea comes from an experiment that partly replaced alfalfa hay with whole
cotton seed and soy-bean hull in the feed of cows, and changes were noted to miRNA expression
in the cow’s serum EVs (Quan et al., 2019).
Zhou et al. (2019) first reported on microbiome changes caused by the intake of bovine
milk exosomes on C57BL/6 mice. Mice fed exosome/RNA-depleted (ERD) and exosome/RNAsufficient (ERS) diets were evaluated and the diets altered bacterial communities at the family
level, notably of Lachnospiraceae, Ruminococcaceae, and an unclassified family in the order
Clostridiales. Dysbiosis in these bacterial communities are related to conditions that include
inflammatory bowel disease, diabetes, and liver disease. It remains unclear if the changes in
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bacterial communities is caused by exosomes, exosomal miRNA, or other cargos (F. Zhou et al.,
2019). Milk exosomes that are not absorbed by mucosal cells may still be involved in biological
pathways, and it is estimated that 75% of miRNA are not absorbed (Manca et al., 2018).
Nonetheless, if exosomes and the associated cargos are playing a role in human health outcomes,
it might be of interest to investigate how commercial processing of milk affects the bovine milk
EVs. Table 2-1 below compares the cargo of bovine and human milk EVs.
Table 2-1 Comparison between human and bovine milk EVs

Protein
(protein species;
mg/dL)

1,963 (van Herwijnen et al., 2016);
5.08 (Bickmore & Miklavcic, 2020)

mRNA
(unique mRNA
sequences)

Present (Lasser et al., 2011),
but not quantified

Bovine Milk EVs
4.8 x 108
(Yamauchi et al., 2019)
Present (Skotland, Sandvig, &
Llorente, 2017), but not yet
quantified
2,032 (Maity, Bhat, Giri, &
Ambatipudi, 2020);
1,718 (Maburutse, Park, Oh, &
Kim, 2017)
19,320
(Hirohisa Izumi et al., 2015)

miRNA
(unique miRNA
sequences)

620
(Liao et al., 2017)

1,472
(Cai et al., 2018)

Number of EVs
per mL
Fatty Acids

2.4

Human Milk EVs
8.9x109
(Bickmore & Miklavcic, 2020)
36.94 mg/dL
(Bickmore & Miklavcic, 2020)

The Commercial Processing of Raw Milk and Effect on Extracellular Vesicles
Milk has been processed by humans for millennia: yoghurt dates back to 5,000 B.C. (Jelen,

1998). Formally, raw milk has been processed since the beginning of the 20th century, when the
U.S. Public Health Service (USPHS) released the Standard Milk Ordinance, assisting
pasteurization programs for milk. The 2017 Grade “A” Pasteurized Milk Ordinance describes
processing procedures, standards of identity of diverse dairy products, and information on
technical concerns for the safety and quality of dairy manufacturing (USPHS & FDA, 2017). The
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21CFR131.110 details the requirements for specific standardized milk and cream sold in the
USA, including product characterization, labeling, and methods of analysis (FDA, 2020).
Processing treatments such as pasteurization, homogenization, sterilization, and spraydrying are applied to milk in order to ensure safety, quality, extend shelf-life, or manufacture
different types of products. A schematic representation of whole milk processing is presented in
Figure 2-2. In the United States, sales of raw milk are legal in retail stores only in 13 states,
while limited in 17 states and illegal in 20 states (CDC, 2017a). Milk may be pasteurized to
ensure destruction of microbial pathogens and extend shelf-life. Different time and temperature
combinations may be utilized as critical limits and are outlined on 21CFR131.3, varying from
145 °F (63 °C) for 30 min (the ‘Holder’ process), 161°F (72°C) for 15 s (the high-temperature
short-time or HTST process), to higher-heat and shorter-times (or ‘flash pasteurization’): 191 °F
(88 °C) for 1s, 204 °F (95 °C) for 0.05 s, to 212 °F (100 °C) for 0.01 s (Fellows, 2017). Ultrapasteurized products must be thermally processed at or above 280 °F (138 °C) for at least 2 s (the
ultra-high-temperature or UHT process), in order to produce an extended shelf-life product under
refrigerated conditions (21CFR131.3). However, a common practice performed in the industry is
to establish operating limits as a way of avoiding deviations from the critical limits in a process.
In the case of pasteurization, the operating limits would be temperature and time combinations
higher than the previously mentioned critical limits. Utilizing an operating limit allows for
process adjustments if any unexpected variability or deviation occurs, ensuring compliance with
regulations, product quality and safety, and avoiding re-work or losses (Blakistone et al., 2011).
While the critical limit for HTST pasteurization is established at 72 °C for 15 s, the operating
limit could be set at 77 °C for 20 s. In the case of UHT pasteurization, the critical limit is 138 °C
for 2 s, while an adequate operating limit would be 143 °C for 3 s.
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Pressure homogenizing systems are used to reduce the size of fat globules in dispersion in
a milk matrix by the application of intense shearing forces. The disruption of fat globules is
achieved by the turbulence resulting from the shearing forces applied to the product, as well as
from impact forces the product is subject to inside the system, and shock waves produced from a
drop in pressure created when vapor bubbles implode in the liquid (‘cavitation’). Pressure
homogenizers are often used before the heat treatment of milk products, in a so-called upstream
homogenizing system (Fellows, 2017). Yet, the homogenization of milk in cold conditions
(below 40 °C), in which the fat is solidified, results in incomplete dispersion of the fat phase.
Therefore, milk is typically preheated before homogenization thus decreasing milk viscosity and
accomplishing better homogenization results. Homogenization pressures vary with the product
between 10 and 25 MPa (1450 to 3625 psi) (TetraPak, 2015).
As technology and consumers’ needs evolve, innovative processing methods
(fermentation, enzyme, protein modifications) are leading to the development of new or
improved dairy products that go beyond pasteurized milk. Although these industrial treatments
may positively alter the physicochemical properties of milk, resulting for example increased
yield, gelling and foaming characteristics, they may as well negatively impact the bioactive
compounds present in milk, including EVs (Fox, Uniacke-Lowe, McSweeney, & O'Mahony,
2015). Because preserving the beneficial components in milk is of high interest (Section 2.2
above), it is important to understand how processing treatments affect the nutrient and bioactive
compound profile.
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Figure 2-2 Schematic representation of whole milk processing. Adapted from Howard et al.
(2015); Michalski & Januel (2006).
2.4.1

Processing Impacts the Nutritional Profile of Bovine Milk
Raw bovine milk is composed on average of 87.3 % water, 3.7 % fat, 3.4 % proteins, 4.8

% lactose and 0.7 % ash (mineral) content (Jenness, 1974; Lindmark-Månsson, Fondén, &
Pettersson, 2003). Dairy processing treatments have benefits that include the purpose of food
safety, but they can also result in detrimental reactions that include the Maillard reaction, lipid
oxidation, proteolysis and protein cross-linking. The Maillard reaction occurs in pasteurization
and not only leads to browning but can also lower digestibility of proteins and reduce
bioavailability of lysine from the reaction of lactose and lysine (Abd El-Salam, 2014;
Erbersdobler & Somoza, 2007). Homogenization causes the formation of fat-protein complexes
and affects the phospholipid content of the milk fat globule membrane (MFGM). Pasteurization
can destroy water-soluble vitamins. The HTST process results a 10 % loss in vitamin B and 25 %
in vitamin C, while more significant losses occur in UHT, 20 % in vitamin B and 30 % in
vitamin C (Michalski & Januel, 2006). Pasteurization affects the biological activity of
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Immunoglobulins, glycoproteins that play a critical role in recognizing and binding to antigens
(viruses, protozoa, bacteria and toxins), and in contributing to immunological supplementation,
especially in infants (Pagnoncelli, de Melo Pereira, Fernandes, Tanobe, & Soccol, 2017; Ustunol
& Sypien, 1997). Homogenization and spray-drying impact droplet size, aggregation and the free
fat content of milk, which can affect the powder’s flowability and sensory characteristics due to
oxidation (Vignolles et al., 2009). Casein micelles are destabilized by processes such as
ultrafiltration, evaporation, spray-drying, freezing, and high pressure treatments (500 MPa) (Fox
et al., 2015).
Furthermore, the composition of raw milk may also vary during processing, with
skimming: reduced fat milk contains 2 % milk fat, low-fat milk contains 1 % milk fat (FDA,
2019a). These differences in composition may require different protocols depending on the
material being analyzed. It is the case for example of RNA: the lipid fraction in human milk is 8fold richer in total RNA content than skim milk, as RNA are conserved within cells, fat globules
or vesicles (Alsaweed et al., 2015). In this sense, for an accurate characterization of the RNA
composition, it would be important to take into consideration the genetic material variability and
the milk fraction being analyzed. Different processing methods may result products with varying
ratios of nutritional and bioactive compounds.
2.4.2

Processing Impacts the Composition of Bovine Milk Extracellular Vesicles
The dairy industry is seeking process improvement focusing on the maintenance

throughout manufacturing of bioactive compounds present in raw milk (Fox et al., 2015).
Therefore, a rethinking of the unit operations utilized might be necessary, notably of the
previously mentioned processes that are related to detrimental reactions: homogenization,
pasteurization, spray-drying. A similar approach to the improvement proposed from regular low
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temperature low time pasteurization to HTST, which achieved the same effect of destroying
microorganisms, with an improvement on the preservation of vitamins.
The resilience of cow’s milk miRNA and mRNA upon exposure to low pH and RNase
treatment suggest it might be resistant to the industrial manufacturing process (H. Izumi et al.,
2012). Some literature suggested that, unlike macrophage-derived EVs, the size and particle
concentration of EVs in milk did not show any significant differences after boiling (for 15 min at
105 °C) and freezing (in liquid nitrogen), possibly as a result of the lipid bilayer membrane
protection (Pieters et al., 2015). However, these findings warrant further investigation, since
pasteurized milk contains fewer or no intact EVs (Kleinjan et al., 2021). In addition, high heat
treatments such as UHT and boiling significantly eliminated the majority of dairy milk miRNA
(Kirchner, Pfaffl, Dumpler, von Mutius, & Ege, 2016). Skotland, Hessvik, Sandvig & Llorente
(2019) found that exosomes have a higher lipid order and show greater stability against
detergents, when compared to other EVs (ApoBDs and microvesicles). Additionally, milkderived EVs have shown stability to freezing and can be stored in -80 °C for up to 1 year (Kalra
et al., 2013; Pieters et al., 2015; Théry, Amigorena, Raposo, & Clayton, 2006). However,
repeated freeze-thaw cycles may result loss of exosomal RNA and should be avoided (Baddela et
al., 2016).
It has been suggested that the shear forces from milk homogenization compromise
exosome structure, thus decreasing the miRNA content by an average of 50 %. Pasteurized,
store-bought whole milk has about a third of the miRNA in raw milk. Even microwave heating
of milk may cause a loss in miRNA – miR-29b decreased by 40 % after heating (Howard et al.,
2015). Generally, the manufacturing of dairy products decreases the concentration of miRNA in
milk, notably in yoghurt, possibly as a result of the large amounts of RNases produced by
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fermentation microbes (Howard et al., 2015). The detrimental effects of processing on these
bioactive compounds should be taken into consideration so that their activity is not affected, and
their benefits maximized.
Human milk plays an essential role on infant development, immunity and health
(Alsaweed et al., 2016). The epigenetic signaling, the potential to regulate human gene
expression, depends on the high miRNA content in human milk. Commercial infant formula
does not carry miRNA in sufficient amounts, which may affect metabolic and immunological
development of infants who rely on infant-formula based nutrition (C. B. Melnik & G. Schmitz,
2017). Additionally, Izumi et al. (2012) suggest that some types of mRNA could not be detected
in extensively hydrolyzed formula, fed to milk-allergic infants, because this type of formula goes
through protease treatment and is passed through a filter to eliminate large peptides. Since
peptides can be as large as 10 kDa, roughly 2.84 nm, they are much smaller than EVs (40-1000
nm) (Erickson, 2009; H. Izumi et al., 2012).
2.5

Rationale and Significance
EVs have been a trending topic in recent scientific research, especially the impact of EVs

in human health, and the role of human milk EVs in infant development. The major miRNA in
both human and bovine milk overlap (Benmoussa & Provost, 2019). Further research is needed
to characterize the similarity of other EV cargos in bovine and human milk, but Howard et al.
(2015) suggest that raw milk EVs may be damaged during processing. There is a need to
understand if this affects the nutritional profile of commercial infant formula, since it is a highly
processed product obtained from raw milk. Wesolowska et al. (2018) and Michalski & Januel
(2006) reported on the effects of high pressure processing and homogenization, respectively, on
bioactive milk components, but without a special regard to EVs. H. Izumi et al. (2012) compared

23

the RNA content in store-bought commercial infant formula to raw milk. Pieters et al. (2015)
found bovine-milk EVs isolated from commercial milk to be stable to treatments at low pH,
boiling and freezing. Howard et al. (2015) identified losses to specific miRNA during processing
of raw milk, speculated to be a result of exosome membrane disruption, but the effects on the
structure of EVs was not evaluated.
The objective of this study was to isolate, characterize and compare the content and
composition of EVs obtained from raw milk, the reference, to EV samples isolated from varying
processing treatments. Applying the treatments in-lab to one starting material (raw milk, the
control) in a pilot plant mimicking large scale production provides an adequate parameter for an
understanding of which treatments affect EVs and how. Understanding which unit operations are
most critical to the preservation of these bioactive compounds allows for the investigation of
what impact processing has on bovine-milk EV’s content and composition. We hypothesize that
the industrial processing of raw bovine milk affects cargo, composition, and concentration of
bovine milk EVs, attenuating the benefits of these bioactive compounds for human health.
The understanding of how processing treatments affect bovine milk EVs is significant
because it provides input for future studies. Our findings may be useful for investigations on
innovative technologies in dairy processing, notably of infant formula, with a focus on the
preservation of EVs. Building on the knowledge we provide may result in novel bovine milkbased infant formula innovations that mimic the bioactive components present in human milk.
A continuous improvement process approach is necessary in overcoming the challenges
of preserving or improving the quality of raw materials, the nutritional benefits of the finished
product, while also ensuring safety for the consumer. The concept of minimal processing and the
use of new non-thermal or alternative technologies has been proven necessary in the food

24

industry (Korhonen, 2002). The results obtained from this study on the analyses of milk
processing treatments should provide input for possible changes on dairy processing with a focus
on the preservation of EVs and other bioactive compounds.
The development of functional foods includes identifying desired biomolecules,
developing a processing technology to preserve them in the end-product, and testing their
efficacy in humans (Korhonen, 2002). A challenge in the food industry is coming up with costeffective large-scale methods to produce bioactive compounds (Fox et al., 2015). Further
research is still needed on establishing the role of EVs and each of their cargos in human health,
but it already reveals as an interesting line of research that, similarly to other bioactive
compounds, can be used for the benefit of human health.
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3

EXPERIMENTAL DESIGN
The experimental design overview is outlined (Figure 3-1). EVs were isolated from raw

and processed bovine milk samples. The Minimal Information for Studies of EVs (MISEV)
guidelines for verification of EVs are utilized in this method for collecting data for the
characterization of the EVs in raw bovine milk, the starting material (Théry et al., 2018). Further
analyses on the concentration of EV miRNA complement the EV characterization. EVs isolated
from processed milk samples will be characterized in regards to the particle concentration, size,
and cargo (protein and miRNA concentrations). These analyses should allow for comparison
between raw milk EVs and those isolated from different processing treatments commonly
employed in the industry.

Figure 3-1 Experimental design overview of The Impact of Processing on the Content and
Composition of Bovine Milk EVs
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4

ISOLATION AND VERIFICATION OF EXTRACELLULAR VESICLES FROM
RAW BOVINE MILK

4.1

Introduction
Bovine milk EVs are bioactive compounds containing RNA, proteins, and fatty acids

enclosed by a phospholipid bilayer, which provides stability in the human gastrointestinal tract
and absorption in the intestine (H. Izumi et al., 2012). The content and composition of BM EVs
may contribute to human health outcomes. BM EV miRNA are absorbed by humans in
meaningful amounts, sufficient to alter human gene expression (Baier et al., 2014). Changes in
mice microbiome have been reported after BM exosome intake, but it remains unclear if these
were resulting from exosomes, exosomal miRNA, or other cargos. Yet, dysbiosis in these
bacterial communities could be related to IBD, diabetes, or liver disease (F. Zhou et al., 2019).
Furthermore, other BM EV cargos such as fatty acids, specific proteins, and other RNA (noncoding RNA, transfer RNA, ribosomal RNA) still warrant further investigation regarding their
functions in milk and health implications in humans. Literature is limited on describing the
variations in EV content and composition across bovine milk sourced from cattle of varying
breeds, on different diets or periods of lactation.
Several methods for the isolation of EVs can be utilized. EV populations include exosomes,
ectosomes, microparticles, microvesicles, or apoptotic bodies, although a consensus has not yet
been reached on these vesicle denominations. Recently, guidelines from the International Society
of Extracellular Vesicles (ISEV) have been released on the minimal information for studies of
EVs (MISEV). This document serves as a guide for authors on the isolation and verification
procedures that ensure successful and reliable isolation of EVs (Théry et al., 2018). This
minimum information was developed in an attempt to ensure rigor and reproducibility in the
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study of EVs. Briefly, the MISEV recommends the characterization of EVs by: (i) quantitative
description of source of EVs; (ii) quantitative assessment of EV preparation by total protein
amount, total particle number or lipid quantification; (iii) global characterization showing at least
three positive and at least one negative protein marker; (iv) characterization of single vesicles
utilizing two complementary techniques such as high-resolution imaging and single particle
analysis techniques estimating biophysical features of EVs (Théry et al., 2018).
There is a need for the standardization of studies on EVs so that the knowledge on these
vesicles continues to expand. The isolation and characterization of human milk EVs following
MISEV guidelines has been described in literature (Bickmore & Miklavcic, 2020). To date, no
studies have focused on isolating and verifying raw bovine milk EV content and composition
following the recently updated MISEV guidelines. Reporting the content and composition of BM
EVs according to the MISEV further benefits studies on BM EVs in areas that include a more
thorough understanding of EV subtypes, the roles of EV cargos, similarities between human milk
EVs and BM EVs, and the importance of EVs to infant nutrition.
4.2
4.2.1

Materials and Methods
Raw Bovine Milk Characterization
This research has received exempt review approval from Chapman University’s

Institutional Review Board (IRB-21-33). Two different batches (M1 and M2) of pooled raw
bovine milk samples were obtained from Stremicks Heritage Foods (Santa Ana, CA) and
processed at Chapman University (Orange, CA) in a pilot-plant scale food processing laboratory.
The M1 batch had been received at the dairy facility the evening prior to collection, and the M2
batch had been received the morning it was collected. The two batches represent experimental
replicates and all results are reported as mean ± standard deviation (SD). Milk properties (% fat,
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protein, lactose, total solids, solids-not-fat) were assessed using a Milkoscan (Foss A/S, Hillerod,
Denmark). Within 24 h, raw milk was transported to Chapman University in sealed bags placed
on ice and stored (4°C). Within 72 h of transport to campus, raw milk was defatted.
4.2.2

Extracellular Vesicle Isolation
A differential centrifugation protocol was used for the isolation of EVs from raw BM (Li

et al., 2019; Munagala, Aqil, Jeyabalan, & Gupta, 2016). The isolation was performed using a
benchtop centrifuge (Sorvall Legend X1R, Thermo Fisher Scientific, Waltham, MA, USA)
equipped with a fixed angle rotor (F13-14x50cy, Thermo Fisher Scientific, Waltham, MA, USA)
for low-speed centrifugations (below 100,000×g), and an ultracentrifuge (Optima XE-90,
Beckman Coulter, Brea, CA, USA) equipped with a fixed angle rotor (Type 50.2 Ti, Beckman
Coulter, Brea, CA, USA) for high-speed centrifugations (at or above 100,000×g).
EVs were isolated from raw milk as outlined (Figure 4-1). A starting volume of 45 mL of
raw bovine milk per falcon tube was utilized for the 1st centrifugation spin, two falcon tubes per
batch, for a total of 90 mL. Milk samples were defatted by centrifuging at 2,000×g for 10 min at
4 °C, and then at 12,000×g for 40 min at 4 °C before the upper fat layer was removed using a
spatula. Then, the supernatant was filtered through a cheesecloth (US Cat. No. 06-665-29,
Thermo Fisher Scientific, Waltham, MA, USA) and stored (-80 °C) until EV isolations and
downstream analyses were performed. Prior to isolation and characterization, the defatted milk
samples were thawed ~12 h at 4 °C. To remove cell debris from the freeze/thaw steps, the
defatted milk tubes were spun at 5,000×g for 30 min at 4°C and the supernatant was removed
without disturbing any debris from the upper layer or from the pellet. A spin at 10,000×g for 30
min at 4°C further resolved the supernatant before ultracentrifugation (UC). The supernatant was
then transferred to polycarbonate UC tubes, which were balanced pairwise to the hundredth of a
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gram using 1x phosphate-buffered saline (PBS) and the mass of PBS added was recorded.
Ultracentrifugation was then performed at 100,000×g for 60 min at 4 °C to remove casein
micelles, which are similar in size and density to EVs. The pellet obtained was discarded and the
supernatant was spun at 130,000×g for 60 min at 4 °C to obtain the EV pellet. UC spins were
performed with the acceleration and deceleration set to maximum. After the spin, the supernatant
was completely removed and discarded. The pellet was resuspended in 3 mL of 1x PBS, a
volume equal to one fifth of the volume of milk supernatant placed in the ultracentrifuge.
Aliquots (1 mL) of resuspended EV pellets were transferred into microtubes and stored (4 °C).
To account for quantitative aspects of EV measurements, volume losses during the isolation
procedure were estimated by a composite index of weight of supernatant removed from UC tubes
and visual estimation of volume losses assessed independently by two investigators and then
agreed upon by consensus. Downstream analyses were performed within 72 h of the isolation of
EVs.

Figure 4-1 The differential centrifugation protocol utilized for EV isolation: preparing EVs for
downstream analysis.
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4.2.3

Extracellular Vesicle Characterization
The verification of successful isolation of EVs was conducted following guidance from the

MISEV (Théry et al., 2018) and is depicted (Figure 4-2).

Figure 4-2 MISEV analyses for the characterization and verification of EVs (Théry et al., 2018).
*microRNA concentration analyses are not mandatory for MISEV but performed in this study.
4.2.3.1 Extracellular Vesicle Quantification: Particle, Protein, and miRNA
Concentrations
Nanoparticle Tracking Analysis (NTA) using a ZetaView® PMX120 NTA and the
ZetaView Software Version 8.05.12 SP1 (Particle Metrix GmbH, Inning, Germany) provided
data on the concentration and the instrument was utilized according to manufacturer instructions.
The EVs resuspended in PBS were serial diluted in PBS in order to achieve 100-250 particles per
frame to optimize instrument sensitivity. The NTA cell was washed with PBS after each reading.
A dilution (1:250,000) of polystyrene (100 nm) beads was prepared for autoalignment routine on
the instrument. The post-acquisition parameters were set to a minimal brightness of 20, a
maximum area of 1000 pixels, a minimum area of 20 pixels, a trace length of 15 frames, 5 nm /
Class, 64 classes / Decade. The camera control was set to a sensitivity of 75, a frame rate of 30
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frames per second, and a shutter speed of 100. Measurements were taken in duplicates from each
batch (M1 and M2). The instrument parameters were set at 11 positions and 2 cycles of reading
per position. The instrument automatically detects statistical outliers within the 11 measurements
taken, and these were not taken into consideration for statistical analyses. A minimum of 8 valid
positions were required to accept the data.
Protein concentration in the total BM EV isolation was assessed with a Qubit 4
Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturer
instructions and utilizing a volume of 1 µL of the EV resuspension in PBS. Although not
mandatory for the characterization of EVs by MISEV (Section 4.2.3), analyses on the
concentration of EV miRNA complemented the characterization of the content and composition
of EVs. The Qubit miRNA Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) was
utilized to quantify the concentration of miRNA in the total BM EV isolation using the Qubit 4
Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturer
instructions and utilizing a volume of 10 µL of sample for analyses. For each analysis, three
dilutions were prepared for each batch (M1 and M2) and measurements were taken in triplicate.
Protein to particle ratios are given in µg of BM EV protein to EV particle number.
4.2.3.2 Global Characterization: Antibody Array
The identification of typical positive (Flotillin-1 – FLOT1; intracellular adhesion
molecule – ICAM; clusters of differentiation 81 and 63 – CD81, CD63; ALG-2-interacting
Protein X – ALIX; Annexin-5 – ANXA5; tumor susceptibility gene 101 – TSG10) and negative
(Golgi matrix protein 130 – GM130; epithelial cell adhesion molecule – EPCAM) BM EV
protein markers was performed using an Exo-CheckTM antibody array (System Biosciences, Palo
Alto, CA) according to manufacturer instructions and starting with 50 µL of the isolated EV
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samples resuspended in 1x PBS. The membrane was developed using Clarity Max Western ECL
Substrates (Bio-Rad, Hercules, CA, USA) according to manufacturer instructions and imaged
with a Bio-Rad ChemiDoc Imaging System equipped with a Bio-Rad Image Lab Touch Software
Version 2.2.0.08 (Bio-Rad, Hercules, CA, USA) using the chemiluminescence application.
4.2.3.3 Single Extracellular Vesicle Characterization
Characterization of single vesicles was conducted using two complementary techniques:
Scanning Electron Microscopy (SEM) and Nanoparticle Tracking Analysis (NTA). SEM
imaging was conducted using a Zeiss Gemini Sigma 300 (Zeiss, Jena, Germany) for EV
visualization. EVs were visualized 24 h after isolation. EVs resuspended in PBS were serial
diluted in ddH2O (Figure 4-5) and SEM slides were prepared with 25 µL of dilutions and
allowed to air dry ~ 12 h in sterile petri plates. Samples were coated with a thin layer of
gold/palladium (Au/Pd 80/20%, 99.99% Au/Pd) using a Mini Sputter Coater / Glow Discharge
System SC7620 (Quorum Tech, Laughton, United Kingdom). NTA provided data on the size
distribution of EVs based on particle displacement patterns and was performed as described in
Section 4.2.3.1.
4.3
4.3.1

Results
Raw Bovine Milk Characterization
Characterization of the physical properties of raw BM are detailed (Table 4-1 ) and in

agreement with 21CFR131.110, which states that standardized milk should not have a fat content
lower than 3.25 % and solids-not-fat lower than 8.25 % (FDA, 2020).
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Table 4-1 Physical properties summary of raw bovine milk.
Batch
Fat (%)
Protein (%)
M1
3.64 ± 0.01
3.14 ± 0.01
M2
3.70 ± 0.01
3.16 ± 0.00
Average 3.67 ± 0.04
3.15 ± 0.02
*TS (Total solids); SNF (Solids-not-fat)
4.3.2

Lactose (%)
4.62 ± 0.01
4.55 ± 0.01
4.58 ± 0.04

TS* (%)
12.50 ± 0.02
12.53 ± 0.01
12.51 ± 0.02

SNF* (%)
8.82 ± 0.01
8.79 ± 0.01
8.81 ± 0.02

Extracellular Vesicle Isolation
EVs were successfully isolated from raw bovine milk utilizing the adapted protocol

proposed. However, after the 1st UC spin, a portion of the EV-containing supernatant had a
cloudy appearance, likely caused by particles remaining in suspension, and this debris could coaggregate with the EV pellet if transferred to subsequent isolation steps. To ensure that no debris
is carried on to subsequent isolation steps, a portion of the supernatant is discarded after the 1st
UC spin. In order to account for this volume of EV-containing milk supernatant discarded after
the 1st UC, a loss coefficient of 5% was multiplied by the measurements obtained for raw BM
EV protein, miRNA and particle concentrations. This coefficient was estimated by a composite
index of weight of supernatant removed from UC tubes and visual estimation of volume losses
assessed independently by two investigators and then agreed upon by consensus.

A

B

Figure 4-3 The differential centrifugation protocol resulted in a clear pellet, which was then
resuspended in PBS for MISEV characterization (A: M1; B: M2).
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4.3.3

Extracellular Vesicle Characterization

4.3.3.1 Extracellular Vesicle Quantification: Particle, Protein, and miRNA
Concentrations
The mean unadjusted protein concentration of the total BM EV isolation was 390.55 (±
32.13) µg/mL of raw bovine milk across both batches. The mean raw BM EV concentration was
1.01 x 1010 (± 3.30 x 109) particles/mL of milk. The average protein:particle ratio was 4.02 x 10-8
(± 1.01 x 10-8) µg protein/particle across batches tested. The mean unadjusted miRNA
concentration of total raw BM EV isolation was 484.61 (± 16.78) ng/mL across both batches
(Table 4-2).
Table 4-2 Raw BM EV measurements.
Diameter
(nm)

M1

130.01
± 15.63

Unadjusted
Protein
Concentration
(µg/mL)
411.28
± 27.89

EV
Concentration
(particles/mL)

Protein:Particle
(µg
protein/particle)

1.24 x 1010
± 2.89 x 109

3.32 x 10-8
± 2.40 x 10-9

Unadjusted
miRNA
Concentration
(ng/mL)
495.59
± 9.15

M2

124.18
± 9.17

369.83
± 21.20

7.84 x 109
± 1.81 x 109

4.72 x 10-8
± 1.02 x 10-8

473.63
± 15.61

Average

127.02
± 12.91

390.55
± 32.13

1.01 x 1010
± 3.30 x 109

4.02 x 10-8
± 1.01 x 10-8

484.61
± 16.78

4.3.3.2 Global Characterization: Antibody Array
The results obtained from the exo-check antibody array for both batches (M1 and M2)
were similar. As expected, GM130 and EPCAM resulted negatives, while FLOT1, ICAM,
ALIX, CD81, CD63, ANXA5, TSG101 resulted positives.
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Table 4-3 Expected results and obtained results for the antibody array of raw BM EVs.
Antibody
GM130
FLOT1
ICAM
ALIX
CD81
CD63
EPCAM
ANXA5
TSG101

Expected Result
+
+
+
+
+
+
+

M1
+
+
+
+
+
+
+

M2
+
+
+
+
+
+
+

A

B

Figure 4-4 Antibody array of raw BM EVs (A: M1, B: M2). +cont and -cont represents positive
and negative controls, respectively. EPCAM and GM130 are markers for cellular contamination.
TSG101, FLOT1, ANXA5, ALIX, CD63, CD81, ICAM are positive markers of BM EVs.
4.3.3.3 Single Extracellular Vesicle Characterization
SEM provided broad-field and close-up high-resolution imaging of the raw BM EVs in
both batches, displaying particles with a diameter of ~ 200 nm (Figure 4-5). Raw BM EV
diameters obtained from NTA measurements are summarized (Table 4-2). The mean diameter
was 127.02 (± 12.91) nm, showing a unimodal distribution (Figure 4-6). The collective of the
results presented for single EV characterization provides the information required by MISEV to
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classify EVs according to their biophysical features, revealing mainly small EVs (sEVs < 200
nm diameter), and a much smaller portion of large EVs (lEVs > 200 nm diameter).

Figure 4-5 Images of Raw BM EVs obtained by SEM. (A) M1 broad-field image, 1:1000
dilution, 1µm scale. Electron High Tension (EHT) =10.00 kV, Signal A = SE2, Aperture Size =
30.00um, WD = 10.1 mm, Magnification = 4.89 K X, Specimen Height = 2 mm. (B) M1 closeup image, 1:2,000 dilution, 200nm scale. EHT = 10.00kV, Signal A = SE2, Aperture Size =
30.00 um, WD = 10.3 mm, Mag = 9.13 K X, Specimen Height = 2mm. (C) M2 broad-field
image, 1:3,500 dilution, 1 µm scale. EHT = 10.00 kV, Signal A = SE2, Aperture Size =
30.00um, WD = 7.3 mm, Mag = 4.74 K X, Specimen Height = 2mm. (D) M2 close-up image,
1:3,500 dilution, 200nm scale. EHT = 10.00 kV, Signal A = SE2, Aperture Size = 30.00um, WD
= 7.3 mm, Mag = 4.74 K X, Specimen Height = 2mm.
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Figure 4-6 Size distribution of raw bovine milk EVs. NTA measurements resulted in a
unimodal distribution, with a mean diameter of 130 nm (M1) and 124 nm (M2). A dilution factor
of 1:1,000 was utilized for measurement of M1 samples, and 1:666 for M2 samples. S1, S2 =
sample replicates.
4.4
4.4.1

Discussion
Raw Bovine Milk Characterization
Ninety percent of U.S. dairy cows are Holstein, but other dairy producing breeds include

Jerseys and crossbreeds (Cessna, 2019; HAUSA, 2020). The EV concentration and composition
may vary according to the season, cattle’s breed and diet (Özdemir, 2020). The milk utilized in
this research was a composite of two batches of raw BM obtained from a dairy farm and supplied
to a dairy processing plant, therefore the results obtained represent EVs that would supposedly
be present in commercially available dairy.
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4.4.2

Extracellular Vesicle Isolation
Although initially proposed for this research, a precipitating reagent was not utilized in

combination with the ultracentrifugation (UC) protocol because some literature suggests that the
use of precipitating reagents may result in the coprecipitation of non-EV proteins and impurities
(J. Lobb et al., 2015; Jan Van et al., 2014; Konoshenko, Lekchnov, Vlassov, & Laktionov,
2018). Therefore, a differential centrifugation method was proposed based on previous literature,
and EVs were successfully isolated from raw bovine milk. Differential centrifugation is the most
commonly used EV separation and concentration technique, consisting of a sequence of low and
high-speed spins for the isolation of an EV pellet (Gardiner et al., 2016; Royo, Théry, FalcónPérez, Nieuwland, & Witwer, 2020). The differential centrifugation method may be considered a
low recovery, high specificity method, in which small EVs (Diameter < 200 nm) are isolated
through pelleting in a sequence of high-speed centrifugations. The term “low recovery” is
pertinent to the total amount of EVs, as it has been explored in literature that a subset of EVs
pellet at low ultracentrifugation speeds (Benmoussa et al., 2017).
The first steps in the isolation protocol are performed for sample defatting. Defatting has
been suggested to avoid contamination of the native EV samples with cell debris resulting from
cells lysed during cold storage (Li et al., 2019; Zonneveld et al., 2014). Furthermore, the MFGM
may disintegrate during freezing and thawing of milk samples. The defatting step minimizes
structural rearrangement to MFGM fragments and formation of EV-like nanoparticles (Blans et
al., 2017). The freezing step has been suggested to eliminate cell debris and apoptotic bodies,
facilitating recovery of BM EVs in the differential centrifugation protocol and ensuring the
purity of the isolated EV pellet (Li et al., 2019; Zonneveld et al., 2014).
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It was found that raw milk is more easily defatted and cleared than processed milk,
resulting in a clearer supernatant in the final centrifugation steps and a clear pellet after the last
UC, which contains the isolated EVs. The cloudy appearance of the EV-containing supernatant is
likely caused by particles remaining in suspension and this debris could co-aggregate with the
EV pellet if transferred to subsequent isolation steps. Processed milk has a larger volume of
debris containing supernatant due to changes to the milk matrix derived from processing. Heat
treatments cause denaturation and aggregation of serum proteins, and homogenization increases
interactions between whey and casein, and whey and fat globules (Qi, Ren, Xiao, & Tomasula,
2015). Centrifuging the EVs at a speed higher than 20,000×g removes casein micelles (Blans et
al., 2017). Nonetheless, EV samples isolated from processed whole milk using a differential
centrifugation protocol were found to still contain non-EV protein aggregates (Somiya,
Yoshioka, & Ochiya, 2018).
4.4.3

Extracellular Vesicle Characterization

4.4.3.1 Extracellular Vesicle Quantification: Particle, Protein, and miRNA
Concentrations
The mean protein concentration of raw bovine milk EVs was 390.55 (± 32.13) µg/mL of
raw bovine milk across both batches (Table 4-2). In microvesicle samples isolated from bovine
colostrum using a similar differential centrifugation protocol, a protein content of 4.67 mg/mL
was found, although the authors declared the protein measured was not specifically
microvesicular protein (Maburutse et al., 2017). The protein concentration of bovine milk
exosomes isolated from store-bought skimmed milk using a commercial isolation kit was
reported as 3,290 µg/mL (Carobolante, Mantaj, Ferrari, & Vllasaliu, 2020). Yet evidence
suggests that the use of precipitating reagents may result in the coprecipitation of non-EV
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proteins and impurities (J. Lobb et al., 2015; Jan Van et al., 2014; Konoshenko et al., 2018). For
comparison, the mean protein concentration in raw human milk EVs is about seven times lower
than our results for raw bovine milk, yielding 50.8 (± 1.5) µg/mL of human milk (Bickmore &
Miklavcic, 2020).
The mean raw BM EV concentration was 1.01 x 1010 (± 3.30 x 109) particles/mL of milk
(Table 4-2). Similar results (5x1010 particles/mL) have been obtained from semi-skimmed
commercial milk samples, from EVs isolated using a differential centrifugation protocol
combined with a precipitating reagent (Pieters et al., 2015). Yamauchi et al. (2019) isolated 4.8 x
108 particles/mL from raw bovine milk using a differential centrifugation protocol. The variation
in particle concentration is highly dependable on the isolation method utilized and the biological
fluid from which particles are isolated (Konoshenko et al., 2018). By extending centrifugation
time, a higher yield of vesicles may be obtained, while excessively long centrifugations may
result in protein contaminated pellets (Cvjetkovic, Lötvall, & Lässer, 2014).
The average ratio of protein:particle was 4.02 x 10-8 (± 1.01 x 10-8) µg protein/particle
across batches tested (Table 4-2). Previous studies have found 2 x 10-8 µg/particle in
commercially available semi-skimmed milk isolated using a centrifugation protocol coupled with
a precipitating reagent (Pieters et al., 2015). From store-bought whole milk EVs isolated using a
differential centrifugation protocol, a ratio of 4.17 x 10-9 µg/particle resulted (Somiya et al.,
2018). The yields found in literature are expectedly lower than the results in this study because
the starting material was processed raw milk, and processing leads to the loss of EV subsets and
significantly reduces protein cargo (Kleinjan et al., 2021).
There is evidence on the content of RNA in the bovine whey fraction – not necessarily of
EVs – in mature milk (120 ng/mL) and colostrum (450 ng/mL) (H. Izumi et al., 2012). In
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agreement with these results, the RNA content in microvesicles isolated by sucrose-density
gradient ultracentrifugation is higher in colostrum (284.02 ng/mL) than in mature milk (164.73
ng/mL) (Hata et al., 2010). The concentration of RNA in a raw bovine milk matrix is much
higher: 46,330 ng/mL (Kirchner et al., 2016). However, growing interest on BM EV miRNA and
their potential to alter human gene expression has led this study to focus on miRNA as a
complementary analysis to the required protein quantification proposed by MISEV (Baier et al.,
2014). To our knowledge, this is the first study to report the total concentration of miRNA in
EVs isolated from raw bovine milk. Some studies have quantified specific miRNA in raw milk,
such as miR-200c and miR-29b (Howard et al., 2015). Others have evaluated the profile
expression levels of bovine milk miRNA, without a specific regard to the total concentration of
these short non-coding RNA in milk (Cintio et al., 2020; Kirchner et al., 2016). The mean
miRNA concentration of raw BM EVs was 484.61 (± 16.78) ng/mL milk across both batches
(Table 4-2). The Qubit miRNA Assay Kit utilized has a high degree of selectivity for small RNA
(~20 nucleotides) and demonstrates consistent measurements at levels as low as 0.5 ng small
RNA (FisherScientific, 2015; Wright, de Silva, Purdie, & Plain, 2020).
4.4.3.2 Global Characterization: Antibody Array
Following MISEV guidelines, the exo-check antibody array revealed that the raw BM EV
samples were positive for at least two known positive EV markers (TSG101, FLOT1, ANXA5,
ALIX, ICAM, CD81, CD63) and negative for at least one known negative EV marker (EPCAM
and GM130) (Théry et al., 2018). MISEV guidelines categorizes the tested protein markers on
the Exo-Check antibody array (Table 4-3 and Figure 4-4). The confirmation of at least one
transmembrane or glycosylphosphatidylinositol-anchored (GPI-anchored) protein associated to
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plasma membrane and/or endosomes is required, and the antibody array confirmed the presence
of the non-tissue specific tetraspanins, CD63 and CD81.
One or more cytosolic proteins may be recovered in EVs with lipid or membrane proteinbinding ability, and their presence must also be tested. Results were positive for TSG101,
FLOT1, ANXA5, ALIX. The ALIX marker, also called the Programmed Cell Death 6 (PDCD6)
marker, is involved in exosomal biogenesis and has been identified in 68% of exosome studies
(Mathivanan, Fahner, Reid, & Simpson, 2012; Mathivanan et al., 2010; Record, Subra, SilventePoirot, & Poirot, 2011). A previous study suggested that ALIX is present in higher abundance in
colostrum than in mature milk (Samuel et al., 2017). Standardized milk sold commercially is
required to be “practically free from colostrum” according to 21CFR131.110 (FDA, 2020), yet
the pooled bovine milk samples resulted in ALIX with indeterminate positivity. Although the
intracellular adhesion molecule (ICAM) is not mentioned on MISEV guidelines, it is an integral
component of the membrane and thus a positive marker for bovine milk EVs (ExoCarta, 2021;
Reinhardt, Sacco, Nonnecke, & Lippolis, 2013).
Confirming the absence of negative protein markers ensures that negative protein
markers present in the tissue of origin (lactocytes) are absent from EVs, which confirms the
absence of contaminating cells from where EVs originated and ensures successful isolation of
EVs. EPCAM is an epithelial tissue specific transmembrane protein, considered a negative
marker for raw BM EVs. GM130 is categorized as a secretory pathway protein associated to
other intracellular compartments, as it is derived from the Golgi apparatus and considered a
marker for cellular contamination (Nakamura et al., 1995; Théry et al., 2018).
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4.4.3.3 Single Extracellular Vesicle Characterization
Initially, one of the methods proposed for this research for the verification of EVs
included measuring relative size distribution using a DLS instrument, but the results obtained
through this method are only accurate in samples with a monodisperse particle population, which
could have not been the case in the isolated BM EV population. This possible inaccuracy was
mitigated by performing NTA, which measures the absolute size distribution of particles in a
fluid, and is especially more sensitive to vesicles larger than 100 nm (Van der Pol et al., 2010).
The NTA instrument utilized for this research has a measurement range from 20 nm to 50 µm,
which varies with the properties of the material being measured, e.g. scattering efficiency and
particle migration (ParticleMetrix, 2020).
SEM provided broad-field and close-up high-resolution imaging of the raw BM EVs in
both batches, displaying particles with a diameter of ~ 200 nm (Figure 4-5). The image obtained
from SEM was in accordance with the size distribution results obtained from NTA, which
showed a unimodal distribution (Figure 4-6). Similar size distributions for bovine milk EVs have
been previously evidenced in literature (Munagala et al., 2016; Somiya et al., 2018). The mean
diameter obtained for the raw milk EVs was 127.02 (± 12.91) nm, which agrees with findings
previously described in literature of 125 nm for raw BM EVs (Yamauchi et al., 2019). Larger
populations of vesicles have also been obtained from raw milk, with mean sizes of 154 nm and
178 nm, via an isoelectric precipitation and differential centrifugation protocol (Cintio et al.,
2020). Using an isolation reagent, EVs from store-bought cow skimmed milk measured an
average diameter of 185.8 nm (Carobolante et al., 2020). The variation in mean particle size is
highly dependable on the isolation method utilized and the biological fluid from which particles
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are isolated (Konoshenko et al., 2018). The data herein presented revealed mainly sEVs (< 200
nm, and a much smaller portion of lEVs (> 200 nm diameter).
4.5

Conclusion
The EV characterization performed indicates the feasibility of isolating EVs from raw

BM using the proposed differential centrifugation method for the global and single vesicle
characterization following MISEV guidelines. The content and composition of raw bovine milk
EVs presented in this study will support future research on and beyond bovine milk EVs. The
foundational information presented will allow an exploration of the effects of processing on the
content and composition of bovine milk EVs by comparing raw and processed BM EVs.
Importantly, this information can help narrow the compositional gap between human milk and
bovine milk-based infant formula, thus ensuring that infants obtain the expected bioactive
compounds from bovine milk products.
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5

EFFECTS OF PROCESSING TREATMENTS ON THE CONTENT AND
COMPOSITION OF BOVINE MILK EXTRACELLULAR VESICLES

5.1

Introduction
Due to food safety concerns, raw bovine milk sales are highly regulated in the United

States and even illegal in 20 states. Pasteurization and homogenization are common treatments
applied to milk to ensure destruction of potential microbial pathogens and extend product shelflife. HTST (72 °C for 15 s) and UHT (138 °C for 2 s) are routinely conducted in industry milk
processing. Homogenization (1450 to 3625 psi) can also be performed to reduce the size of fat
globules and prevent the formation of a cream layer on top of the milk, which may be
undesirable for consumers. Milk is typically preheated before homogenization to liquify the fat,
reduce milk viscosity and accomplish better homogenization results (TetraPak, 2015).
Literature suggests that bovine milk miRNA and mRNA are resistant to the industrial
manufacturing process due to encapsulation in EVs (H. Izumi et al., 2012). The membrane
bilayer of EVs may confer protection to the particles, as no difference was found in size or
particle concentration of EVs isolated from semi-skimmed milk after boiling (for 15 min at 105
°C) and freezing in liquid nitrogen (Pieters et al., 2015). However, UHT treatments and boiling
significantly reduced the majority of BM miRNA (Kirchner et al., 2016). Pasteurized, storebought whole milk has about a third of the miRNA found in raw milk. Microwave heating of
bovine milk for 15 s (microwave power not disclosed) caused a decrease of 40% in miR-29b, but
no difference in miR-200c content (Howard et al., 2015). However, another study found different
results: microwaving BM at 305 W resulted in significant losses in miR-200c and no difference
in miR-29b. The differing results are attributed to the different milk sources, RNA extraction and
detection methods (Zhao, Yu, Xu, & Li, 2018).
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Unless intentionally added, commercial infant formulas likely do not contain miRNA and
mRNA in sufficient quantity to support the development of infants (H. Izumi et al., 2012; B. C.
Melnik & G. Schmitz, 2017). Processed yoghurts have decreased concentrations of miRNA
when compared to pasteurized whole milk, possibly resulting from the activity of RNases that
are produced by fermentation microbes. Homogenization decreases miRNA content in BM by
50%, likely due to shear forces that compromise nanovesicle structure and protection of
oligonucleotides (Howard et al., 2015). However, the effects of homogenization and
pasteurization to the miRNA content in milk were not evaluated separately.
Some literature evaluated the effects of processing on EV components utilizing raw milk
as a reference and comparing it to processed milk. However, many studies utilized store-bought
processed milk which derived from different cows, and thus differed from the reference raw milk
EVs (Howard et al., 2015; Kleinjan et al., 2021). The content and composition of these vesicles
varies considerably with the source from which the EVs are isolated. Other studies explored the
effects of processing on specific milk or EV components such as miRNA, however not
specifically in accordance with the 2018 MISEV guidelines as is proposed in this study.
The isolation and characterization of raw BM EVs conducted in accordance with the
MISEV guidelines was described (Chapter 4). Understanding the impacts of processing on the
content and composition of BM EVs can help inform food processing and safety standards to
preserve nutritional bioactives in dairy products. In particular, this information may narrow the
compositional gap between human milk and BM-based infant formula, ensuring that infants
reliant on formulas can obtain bioactive compounds initially present in BM.
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5.2

Materials and Methods
The processing treatments mimicked unit operations commonly used in the commercial

processing of raw milk. The treatments were performed (Figure 5-1), and EVs were isolated and
partially characterized from BM samples from each treatment. Conducting the analysis of all six
samples (Low Temperature Treated Milk – LT; Homogenization Treated Milk – HG; HighTemperature Short-Time Treated Milk – HTST, Homogenized High-Temperature Short-Time
Treated Milk – HGHTST, Ultra-High-Temperature Treated Milk – UHT; Homogenized UltraHigh-Temperature Treated Milk -- HGUHT) provided data for better understanding how EVs
are affected by these unit operations compared to the raw BM reference (Chapter 4).
5.2.1

Raw Bovine Milk Procurement, Characterization, and Sampling for Processing
The two batches (M1 and M2) of raw BM were procured and characterized (Section

4.2.1). At Chapman University (Orange, CA), raw BM was stored at 4 °C. Within 48 h, 6 groups
of raw BM (7 L each) from each batch were processed as described in Figure 5-1. After
processing and within 72 h from receiving BM, 45 mL of all treated BM groups were defatted
and stored at -80 °C until EV isolation and downstream analyses.
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Figure 5-1 Pilot-plant Processing Flowchart. EVs were isolated from each of the 6 clusters of
analysis described above and from raw milk, the reference.
5.2.2

Homogenization and Pasteurization
Homogenization and pasteurization treatments were performed in a Microthermics

Pasteurizer (Model LAB-25 EHVH, Raleigh, NC, USA) with an in-line two-stage GEA
homogenizer (Model Ariete NS2006, Düsseldorf, Germany). The homogenization occurs after
the BM is preheated, before it is pasteurized, and was performed at 2500 psi for all homogenized
treatments (1st stage 2,000 psi; 2nd stage 500 psi). Pasteurization was conducted under two
conditions: HTST at 77 °C for 20 s with a preheat temperature of 49 °C, and UHT at 143 °C for
3.3 s with a preheat temperature of 81 °C. The duration and temperature of each treatment
follows common practices utilized in the industry and are in accordance with 21CFR131.3
(FDA, 2019b).
For homogenization, milk was preheated to 49 °C to facilitate fat particle breakdown
(TetraPak, 2015). In order to isolate the effects of homogenization from the effect of the mild
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heat treatment in preheating, the cluster of analysis LT was performed by treating milk to 49 °C
for 20 s and mimicking the preheating step of homogenization.
5.2.2.1 Homogenization Validation
The efficacy of homogenization was validated using a light scattering instrument
(Coulter, LS 230, Beckman Coulter, Atlanta, GA, USA) to measure volume-average droplet
diameters. After reception of raw milk and processing, the homogenized milk samples were
frozen (-20 °C) for up to 3 days until analysis. Samples were thawed (37 °C) and vortexed before
measurements. Distilled water was used as a background solvent. The refractive index for milk
fat was set at 1.46 and at 1.33 for the aqueous continuous phase (Ransmark, Svensson, Svedberg,
Göransson, & Skoglund, 2019). Measurements were taken in triplicate.
5.2.2.2 Pasteurization Validation
Alkaline phosphatase (ALP) is an enzyme present in milk that is commonly utilized as a
process indicator. ALP is heat-resistant, thus inactivation indicates proper milk pasteurization
(Damodaran & Parkin Kirk, 2018). In this study, pasteurization was validated by using
Phosphatesmo MI test strips (Macherey-Nagel, Düren, Germany) for the determination of ALP
in milk, according to manufacturer instructions. A yellow color indicates the presence of
functional ALP and a white color indicates inactivation of ALP.
5.2.3

Processed Bovine Milk Extracellular Vesicle Isolation
EVs were isolated from the processed BM using differential centrifugation (Section

4.2.2). A standardization coefficient was proposed for all concentration measurements, based on
findings from the isolation of EVs on the different processing treatments (Sections 4.3.2, 5.3.2).
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5.2.4

Processed Bovine Milk Extracellular Vesicle Characterization
EV size distribution, particle, protein and miRNA concentrations were assessed (Sections

4.2.3.3, 4.2.3.1) from all processed BM and compared to raw BM as a reference.
5.2.5

Statistical Analysis
Statistical analyses were conducted and images were generated using the RStudio

Software Version 1.2.1335 (RStudio inc. 2019, Boston, MA, USA). The data obtained did not
satisfy requirements for parametric ANOVA analyses due to heteroscedasticity. Thus, nonparametric statistics (Kruskal-Wallis) was used for the comparison of average particle size and
the concentrations of EV, protein and miRNA across milk treatments (Figure 5-2). Dunn’s post
hoc test was used to test which treatments affected stability of EVs after processing. MannWhitney-Wilcoxon test was used for the comparison of non-homogenized to homogenized
groups. An α = 0.05 was used to designate statistical significance for hypothesis testing. All
results are reported as mean ± standard deviation (SD).

Figure 5-2 Outline of milk samples and BM EV characterization measurements. All
measurements were taken from two batches (M1 & M2) and replicated (described in Sections
4.2.3.1 and 4.2.3.3).
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5.3
5.3.1

Results
Homogenization and Pasteurization Validation
The size distribution curves obtained for raw milk, HG, HGHTST, and HGUHT validate

the homogenization, revealing a higher volume of raw milk with a larger particle diameter (fat
globule size), while homogenized samples shifted the curve peaks to the left as homogenization
pressure was applied and fat globules were disrupted (Figure 5-3).

Figure 5-3 Size distribution analysis for homogenization validation (n = 3). Raw milk displays
the largest volume of particles with a peak in the volume % of particles with a diameter of 4.24
µm, while all homogenized samples (HG, HGHTST, HGUHT) resulted in lower peaks and
smaller particle diameters, thus validating the homogenization of samples.
The ALP showed successful pasteurization of milk samples (Figure 5-4). Raw and LT
resulted in positive tests, while pasteurized samples (HTST, HGHTST, UHT, HGUHT)
confirmed the inactivation of ALP enzymes.
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Figure 5-4 ALP Test Results. ALP-inactivated milk samples (HTST, HGHTST, UHT, HGUHT)
appear in white, while active ALP samples (raw, LT) appear in yellow.
5.3.2

Processed Bovine Milk Extracellular Vesicle Isolation
EVs were successfully isolated from raw and processed BM. Non-homogenized samples

had a clear supernatant, while homogenized samples were turbid (Figure 5-5). Non-homogenized
samples (including raw milk) were standardized to a 5 % loss coefficient, and all homogenized
samples were standardized to a 15 % loss coefficient, in order to account for a volume of EVcontaining milk supernatant discarded during isolation (after the first UC step).
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Figure 5-5 Differences in turbidity across treatments after 1st and 2nd UC spins during the EV
isolation using a differential centrifugation protocol.
5.3.3

Processed Bovine Milk Extracellular Vesicle Characterization

5.3.3.1 Extracellular Vesicle Quantification and Size Distribution
The results obtained from NTA measurements for BM EV concentration and diameter
across treatments are summarized (Table 5-1). The concentration of EVs in the raw BM
reference was 1.01 x 1010 (± 3.30 x 109) particles/mL and was significantly higher than the
concentration of EVs in the six treatment groups (Figure 5-6). Homogenization significantly
reduced the concentration of BM EVs compared to non-homogenized samples (p < 0.01).
Similarly, all heat treatments significantly reduced the concentration of BM EVs, when
compared to the raw BM reference (Figure 5-8). HG compared to LT, and HGUHT compared to
UHT caused significant reductions of EV particle concentration (reduced 94 %, p < 0.01 and
reduced 65 %, p < 0.01, respectively). However, homogenizing HTST did not cause a significant
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reduction in the concentration of EVs, compared to HTST. There was no significant difference in
EV concentration across non-homogenized heat-treated samples (LT, HTST, UHT).

Figure 5-6 Boxplot of BM EV concentration across processing treatments. HG resulted in the
greatest loss of EVs across treatments. HG and HGUHT significantly decreased EV
concentration compared to LT and UHT, respectively. HGHTST did not significantly reduce the
BM EV concentration compared to HTST. Medians were compared using Kruskal-Wallis.
Different superscript letters indicate significant differences (n = 44; α = 0.05).
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Figure 5-7 Bar plot of BM EV concentration across processing treatments (n = 44). All
homogenization and heat treatments (LT, HTST, UHT) significantly reduced the BM EV
concentration in raw milk. Bars depict the mean EV concentration across treatments as
percentages of the reference (raw BM).
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B

A

Figure 5-8 (A) Bar plot of BM EV concentration in combined non-homogenized (LT, HTST,
UHT) and homogenized milk (HG, HGHTST, HGUHT). Homogenization significantly reduced
the concentration of BM EVs from non-homogenized samples. Mann-Whitney-Wilcoxon test
was used to compare non-homogenized to homogenized treatment groups. Bars depict the mean,
error bars represent the standard error of the mean. (B) Boxplot of BM EV concentration across
heat treatments, combining non-homogenized and homogenized samples. All heat treatments
significantly reduced the concentration of EVs when compared to the raw BM reference.
Medians were compared using Kruskal-Wallis. Different superscript letters indicate significant
differences (α = 0.05).
The mean EV diameter in raw milk was 127.02 (± 12.91) nm. The diameter of raw milk
EVs was significantly different from all other treatments, except HGHTST and UHT (Figure 5-9,
Table 5-1). The diameter of HGUHT EVs was significantly larger than that of EVs isolated from
all other treatment groups and the raw BM reference (1.16-fold ; p < 0.01). Within nonhomogenized samples, the magnitude of diameter had a greatest decrease in LT (decreased 16 %
; p < 0.01), followed by more severe heat treatments in HTST (decreased 10 % ; p < 0.01) and
UHT (decreased 7 % ; p > 0.05). Homogenization of heated samples may have disrupted smaller
EVs, yielding increased average particle diameter relative to heat treatments alone (Table 5-1).
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Figure 5-9 Boxplot of BM EV diameter across processing treatments. All treatments caused
reductions to the diameter of EVs, except for HGUHT. Homogenization of heated samples
caused an increase in diameter, which was not significantly different between LT and HG or
HTST and HGHTST, but there was significance between UHT and HGUHT. Medians were
compared using Kruskal-Wallis. Different superscript letters indicate significant differences (n =
44; α = 0.05).
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Table 5-1 BM EV measurements across processing treatments. Results are reported as mean ± standard deviation (SD).
Treatment

Homogenized?

Heat
Treatment?

EV
Diameter
(nm)

BM EV
Concentration
(particles/mL)

Raw

No

No

127.02a ±

LT

HG

HTST

HGHTST

UHT

HGUHT

No

Yes

No

Yes

No

Yes

LT

LT

HT

HT

UHT

UHT

Protein:Particle
(µg protein /
particle)

1.01 x 1010a ±

Unadjusted
Protein
Concentration
(µg/mL)
390.55a ±

miRNA:Particle
(ng miRNA /
particle)

4.02 x 10-8a ±

Unadjusted
miRNA
Concentration
(ng/mL)
484.61a ±

12.91

3.30 x 109

32.13

1.01 x 10-8

16.78

1.34 x 10-8

106.21b ±

3.60 x 109b ±

307.30ab ±

2.58 x 10-7ab ±

315.88ab ±

2.45 x 10-7ab ±

14.54

3.06 x 109

17.19

2.44 x 10-7

26.62

2.24 x 10-7

113.44bc ±

2.06 x 108d ±

130.54de ±

5.76 x 10-7b ±

94.45de ±

4.52 x 10-7b ±

19.03

2.63 x 107

28.87

4.13 x 10-8

4.71

4.82 x 10-8

114.87bc ±

2.20 x 109b ±

269.71bc ±

1.25 x 10-7ab ±

181.95bc ±

8.36 x 10-8ab ±

7.95

2.95 x 108

14.47

1.26 x 10-8

8.66

7.40 x 10-9

121.34ac ±

1.65 x 109bc ±

181.65ce ±

1.11 x 10-7ab ±

120.05ce ±

7.26 x 10-8ab ±

14.90

4.28 x 108

24.63

1.41 x 10-8

26.27

7.03 x 10-9

117.78ac ±

3.15 x 109b ±

68.12df ±

2.85 x 10-8a ±

98.02de ±

4.10 x 10-8a ±

9.13

1.78 x 109

15.07

1.32 x 10-8

10.93

2.16 x 10-8

146.86d ±

1.10 x 109c ±

38.91f ±

3.30 x 10-8a ±

51.56d ±

4.87 x 10-8a ±

17.78

2.48 x 108

9.20

3.32 x 10-9

9.43

3.55 x 10-9
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5.16 x 10-8a ±

5.3.3.2 Protein Quantification
The BM EV protein concentration across treatments is summarized (Table 5-1), and a
boxplot depicts the variations in the total unadjusted protein concentration of the total BM EV
isolation across treatments (Figure 5-10). The unadjusted protein concentration of the total raw
reference BM EV isolation was 390.55 (± 32.13) µg/mL. The mild preheat treatment of LT did
not significantly reduce the unadjusted protein concentration of the total BM EV isolation
compared to the raw BM reference (reduced 21 %). All other treatments were significantly
different than the raw BM reference. The higher the temperature of processing, the lower the
unadjusted protein content across non-homogenized BM EV samples (Figure 5-11). HGUHT
resulted in the greatest decrease in unadjusted protein content when compared to the raw BM
reference (decreased 90 %; p < 0.01). Homogenization reduced the unadjusted protein
concentrations of the total BM EV isolations from the respective non-homogenized heat-treated
samples, but not to the same extent for all treatments (Figure 5-10). In combination with LT,
homogenization reduced the unadjusted protein concentration from the EV isolation in HG by 58
% compared to LT alone (p < 0.01), while HGUHT reduced by 43 % from UHT (p > 0.05), and
HGHTST reduced by 33 % from HTST (p > 0.05).
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Figure 5-10 Boxplot of unadjusted protein concentrations of total BM EV isolations. The
unadjusted protein concentrations of the total BM EV isolations were significantly lower in all
samples when compared to the raw BM reference, except for LT. The unadjusted protein
concentration of the total BM EV isolations reduced with increasing heat treatment temperature.
Combining homogenization with the LT treatment (in HG) resulted in a significant reduction in
proteins, but homogenization of pasteurized samples did not result in significant differences from
the respective pasteurized non-homogenized samples (HTST and HGHTST or UHT and
HGUHT). Medians were compared using Kruskal-Wallis. Different superscript letters indicate
significant differences (n = 18; α = 0.05).

61

Figure 5-11 Bar plot showing effects of homogenization and heat treatments on unadjusted
protein concentrations of the total BM EV isolations (n = 18). Bars depict the mean unadjusted
protein concentration of the total BM EV Isolation across treatments as percentages of the
reference (raw BM).
The raw BM reference yielded 4.02 x 10-8 (± 1.01 x 10-8) µg protein/particle, when
adjusted to total particle number. Even though HG decreased the concentration of EVs in raw
milk the most (Table 5-1), the remaining EVs had the highest protein density across all
treatments. The ratio of protein-to-particle in the raw BM reference was only significantly
different from HG, for which a 14.3-fold increase was observed (p = 0.04) Figure 5-12). The
protein:particle ratios increased for LT and HTST treated samples, and decreased for UHT
treated samples, when in comparison to raw BM reference (p > 0.05).
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Figure 5-12 Boxplot of protein concentrations adjusted to total particle number from BM EV
isolations. Only HG showed a significant difference from the raw BM reference. Medians were
compared using Kruskal-Wallis. Different superscript letters indicate significant differences (n =
4; α = 0.05).
5.3.3.3 miRNA Quantification
The unadjusted miRNA concentrations of the total BM EV isolations are summarized
(Table 5-1). The unadjusted miRNA concentration of the total raw BM EV isolation was 484.61
(± 16.78) ng/mL. There was a decrease in the unadjusted miRNA concentration of the total BM
EV isolations in the processing treatment groups compared to the raw BM reference (Figure
5-13). All processing treatments except for LT resulted in significant differences in the
unadjusted miRNA concentration of the total BM EV isolations compared to the raw BM
reference (Figure 5-13). Both pasteurizations (HTST and UHT) and the homogenized treatments
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significantly reduced the unadjusted miRNA concentrations of the total BM EV isolations when
compared to the raw BM reference (Figure 5-14). HGUHT decreased the unadjusted miRNA
concentration of the raw BM reference the most (decreased 89 %; p < 0.01).

Figure 5-13 Boxplot of unadjusted miRNA concentrations of total BM EV isolations. The
unadjusted miRNA concentrations of the total BM EV isolations were significantly decreased in
each treatment group compared to the raw BM reference, except for the mild heat treatment of
LT. The reduction in unadjusted miRNA concentration of BM EV isolations was directly related
to the magnitude of the heat treatment temperature. Combining homogenization with the LT
treatment (in HG) resulted in a significant reduction in miRNA, but homogenization of
pasteurized samples did not result in significant differences from the respective pasteurized nonhomogenized samples (HTST and HGHTST or UHT and HGUHT). Medians were compared
using Kruskal-Wallis. Different superscript letters indicate significant differences (n = 18; α =
0.05).
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Figure 5-14 Bar plot showing effects of homogenization and heat treatments (no heat treatment,
LT, HT, UHT) on unadjusted miRNA concentration of the total BM EV isolations (n = 18). Bars
depict the mean unadjusted protein concentration of the total BM EV Isolation across treatments
as percentages of the reference (raw BM).
The miRNA concentrations adjusted to total particle number are reported (Table 5-1,
Figure 5-15). Increases in the ratio of miRNA:particle were noticed when comparing raw (5.16 x
10-8 ± 1.34 x 10-8 ng miRNA/particle) to LT (4.75-fold ; p > 0.05), HTST (1.62-fold ; p > 0.05),
and HGHTST (1.41-fold ; p > 0.05), yet it was only significant for HG (8.76-fold ; p = 0.05).
Although not significantly, the ratios decreased when in comparison to raw in UHT (decreased
21 %) and HGUHT (decreased 6 %).
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Figure 5-15 Boxplot of miRNA concentrations adjusted to total particle number from BM EV
isolations. HG caused an increase (8.76-fold ; p = 0.05) in the adjusted miRNA concentration in
comparison to the raw BM reference. Reductions were identified only in UHT (reduced 21 % ; p
> 0.05) and HGUHT (reduced 6 %). Medians were compared using Kruskal-Wallis. Different
superscript letters indicate significant differences (n = 4; α = 0.05).
5.4
5.4.1

Discussion
Homogenization and Pasteurization Validation
Homogenization of BM was successfully validated by a size distribution analysis

comparing these samples to the raw BM reference (Figure 5-3). When milk is homogenized, it is
subject to high pressures and high liquid velocity, which causes fat globules to be disrupted and
the particle diameter to be reduced (Fellows, 2017). The size distribution curve represents a
higher volume of raw milk samples with a larger particle diameter (fat globule size), while the
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homogenized samples shifted the curves to the left as homogenization pressure was applied and
fat globules were disrupted. The ALP test successfully validated the pasteurization of milk
samples (Figure 5-4). ALP is an intrinsically occurring enzyme in milk, commonly utilized as a
processing control for the effectiveness of milk pasteurization because it has a similar D-value to
heat-resistant pathogens (Fellows, 2017). The raw BM reference sample tested has the activated
enzyme and showed a positive result. The mild treatment of preheating milk (LT) also displayed
a positive result since it was heated to 49 °C for 20 s, which doesn’t characterize a pasteurization
treatment. At a temperature of 50 °C, it would take 90 min for ALP to be completely inactivated
(Erkmen, Sekeroglu, & Fadiloglu, 2004). ALP is completely inactivated after a 16 s treatment at
70 °C (McKellar et al., 1994). Hence, the negative readings obtained for the activity of ALP
enzyme in HTST, HGHTST (77 °C for 20 s), UHT, and HGUHT (143 °C for 3.3 s) confirmed
adequate sample pasteurization.
5.4.2

Processed Bovine Milk Extracellular Vesicle Isolation
Processed BM EVs were successfully isolated from the raw BM reference and processed

samples. A caveat inherent to applying the same method for the isolation of EVs from samples of
milk processed in varying manners is the unequal volumes of debris containing supernatant
across treatments. All non-homogenized samples had a clearer supernatant, while all
homogenized samples were turbid (Figure 5-5). In order to account for these differences, the
results for all concentration measurements (EV, protein, miRNA) were multiplied by a loss
coefficient (5 % for non-homogenized, 15 % for homogenized treatments), similarly to what was
described and discussed above (Sections 4.3.2, 4.4.2).
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5.4.3

Processed Bovine Milk Extracellular Vesicle Characterization

5.4.3.1 Extracellular Vesicle Quantification and Size Distribution
The particle concentration in raw milk was significantly higher than all other treatments
(Figure 5-6). All non-homogenized heat-treated samples resulted in a significantly decreased EV
population in comparison to raw, but there was no significant difference across nonhomogenized heat-treated samples. Previous literature reported no significant differences on the
concentration of EVs isolated from HTST and raw milk samples, although HTST treatment
altered EV membrane integrity. UHT treatment substantially decreased the concentration of EVs
in comparison to raw milk (Kleinjan et al., 2021). As previously described for the
characterization of raw BM EVs, the DLS performs accurately in the size determination of
particles in monodisperse samples, while the NTA instrument describes the size distribution of
particles in polydisperse fluids, yet it is suggested to be more sensitive to vesicles larger than 100
nm (Van der Pol et al., 2010). The NTA instrument utilized for this research has a measurement
range from 20 nm to 50 µm, which varies with the properties of the material being measured, e.g.
scattering efficiency and particle migration (ParticleMetrix, 2020). Previous research suggests
that samples of EVs treated by UHT lack the typical light-scattering properties of EVs (Kleinjan
et al., 2021). These changes may affect not only the NTA measurements for EV concentration,
but also for particle diameter, and remain to be further investigated. The whey supernatant
obtained using an ultracentrifugation method had a higher protein content when compared to
whey treated with hydrochloric acid or acetic acid (Rahman et al., 2019). And another limitation
in quantification methods is that protein aggregates may be counted as particles, hence the
importance of performing a reliable isolation method and a thorough characterization protocol
(Théry et al., 2018).
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Homogenizing the preheated milk (LT) affected BM EVs, resulting the lowest particle
concentration across all treatments in HG (Figure 5-6, Figure 5-7). Similarly, homogenizing
UHT (in HGUHT) caused a significant reduction of EV particle concentration (UHT vs
HGUHT; p < 0.01). However, homogenizing HTST did not cause a significant reduction in the
concentration of EVs (HTST vs HGHTST). It has been speculated that EV membranes are
disrupted by homogenization treatments (Howard et al., 2015). Additionally, homogenization
changes the physicochemical arrangement and may affect the activity of bioactive molecules
(Michalski & Januel, 2006). EVs in raw milk are spherical with a clear lipid bilayer, and the
morphology of EVs subject to homogenization (and pasteurization) was remarkably different
from raw milk EVs (Kleinjan et al., 2021). Changes in EV morphology resulting from
homogenization may be due to the shearing forces and high pressures inherent to this treatment
(Howard et al., 2015). In homogenizers, pressure variations create vapor bubbles that implode
and produce shock waves, thereby disrupting fat globules. Termed ‘cavitation’, this phenomenon
also occurs in ultrasonication through the pressure variations causing microbubbles to be formed
and collapse, releasing large amounts of localized energy and causing particle breakdown
(Fellows, 2017). Ultrasonication is an alternative method to pressure homogenization that may
be used in bovine milk, especially in a laboratory or pilot-scale setting. Ultrasonication consists
of applying low-frequency, high-intensity sound waves (20-100 kHz) through an aqueous
system. In the case of bovine milk, ultrasonication at 22.5 kHz and 50 W homogenizes fat
globules, producing sub-micron level emulsions (Abesinghe et al., 2020; Nguyen & Anema,
2017). Ultrasonication transiently disrupted exosome membranes and led to a 20 % decrease in
exosome concentration (Leiferman et al., 2018).
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Significant differences were evidenced from the diameter of EVs in raw milk to most
other treatments, except from raw to HGHTST (-4 %) and UHT (-7 %) (Figure 5-9). The average
diameter of EVs remaining after heat treatment was reduced, and the most significant decrease
was on LT (16 %), followed by more severe heat treatments (HTST reduced 11 % and UHT
reduced 7 %). Treatment of BM by HTST and UHT has been suggested in previous literature to
affect the morphology of EVs, which didn’t appear perfectly spherical as did raw milk EVs.
Very few membrane-enclosed vesicular structures were detected in BM treated by UHT
(Kleinjan et al., 2021).
In the present study, the average diameter of EVs remaining after treatment by
homogenization and UHT was significantly greater than that of EVs isolated from the other
treatment groups and the raw BM reference. Yet even larger EVs (185.8 nm) have been isolated
from store-bought cow skimmed milk using an isolation reagent (Carobolante et al., 2020).
Nonetheless, it cannot be excluded that the increased diameter of EVs isolated using
precipitating reagents is due to the coprecipitation of non-EV proteins and impurities (J. Lobb et
al., 2015; Jan Van et al., 2014; Konoshenko et al., 2018). Similarly, the increased average
diameter obtained for HGUHT when compared to raw (1.16-fold) may be due to co-isolation of
non-EV particles resulting from heat treatments and homogenization, or the aggregation of EVs
in raw milk when subject to severe processing treatments (Figure 5-16). Heat-induced protein
aggregates are formed during milk processing, and although centrifugation at 25,000×g for 1 h at
20 °C was enough to remove casein micelles, it did not sediment the soluble aggregated protein
complexes. Still, these complexes wouldn’t be responsible for the increase in average diameter
indicated for HGUHT since their diameter is around 50 nm (del Angel & Dalgleish, 2006).
Increased signals for casein and beta-lactoglobulin have been identified in UHT EV samples
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(Kleinjan et al., 2021). While heat treatments used in milk processing do not affect caseins, the
denaturation, aggregation and insolubilization of whey proteins may occur (Michalski & Januel,
2006).
Homogenizing the heated samples increased the average particle diameter (Table 5-1).
With homogenization, MFGM components may be rearranged, and fragments may be released to
the aqueous phase of milk (the supernatant in which EVs are contained). Additionally, casein
micelles may be disrupted and adsorb at the interface in micellar form or as fragments
(Michalski & Januel, 2006). In high-speed centrifugation of milk homogenized at 10 MPa (1,450
psi), pelleting particles of 200-300 nm have been characterized, as well as sedimenting lipidprotein complexes (< 500 nm) (Michalski, Michel, & Geneste, 2002). This evidence illustrates
the variety of particles that may result from processing the complex milk matrix and
understanding the nature of these complexes and how EV isolation procedures may be
maximized warrants further investigation. Furthermore, the differences in average diameter of
particles found across treatments may not necessarily reflect a biological significance, and future
work is needed to understand how isolation methods and storage conditions affect these
measurements.

71

Figure 5-16 Size distribution of raw and HGUHT bovine milk EVs. The increased average
diameter obtained for HGUHT (146.86 nm) may be due to co-isolation of non-EV particles
resulting from heat treatments and homogenization, or the aggregation of EVs in raw milk
(127.02 nm) when subject to severe processing treatments. Measurements were taken in
duplicates from each batch (M1 and M2), averages and diameter peaks are depicted for both
treatments.
5.4.3.2 Protein Quantification
Treatment by HTST and UHT, but not the mild LT heat, resulted in a significant
reduction of the unadjusted protein concentration of BM EV isolations relative to the raw BM
reference. In the present study, the unadjusted protein concentration across non-homogenized
BM EV samples reduced with increasing temperature of processing (Figure 5-11). This is in
accordance with literature, as in pasteurized milk some EV-associated proteins were reduced
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(CD63 and FLOT1) or lost (TSG101), which may be due to heat treatments affecting EV
membrane integrity and denaturing protein structure. Evidence suggests some EV subsets are
more susceptible to pasteurization than others. Specific EV-associated proteins were reduced or
absent in UHT milk, yet non-EV proteins such as casein and beta-lactoglobulin had an increased
signal (Kleinjan et al., 2021). Thermal processing reduces the protein content of milk. With
increased heat, the number of detectable proteins decreases, resulting in greater losses in more
severe heat treatments such as UHT and up to 50% in boiling (Brick et al., 2017).
Homogenizing samples reduced the BM EV unadjusted protein content from the
respective non-homogenized heat-treated samples, but not to the same extent for all treatments
(Figure 5-10). The population of EVs remaining after homogenization of mildly heated milk
(HG) had a significantly lower (- 58%) unadjusted protein concentration compared to heated
milk alone (LT), but homogenization of samples pasteurized by HTST and UHT (HGHTST and
HGUHT) did not result significant differences from the respective non-homogenized samples (33 % from HTST and -43 % from UHT). This agrees with literature, as no additional detrimental
effects to the protein cargo of BM EVs resulted from homogenization of heat-treated samples
(Kleinjan et al., 2021).
Evaluating ratios of the quantified measurements, including the protein:particle ratios,
provides useful measures of the purity of isolated vesicles (Théry et al., 2018; Webber &
Clayton, 2013). The raw BM reference yielded a ratio of 4.02 x 10-8 (± 1.01 x 10-8) µg
protein/particle. It has been suggested that the purest vesicular preparations of cultured cells have
ratios below 3.33 x 10-11 µg protein/particle, yet in the case of biological fluids the ratio can be
higher: 1.03 x 10-9 µg protein/particle (Webber & Clayton, 2013). Further experimental
investigations are needed to define purity ratios for raw BM EV isolations, taking into
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considerations the varying isolation methods, the complexity of the milk matrix, and its high
protein content.
Comparing all treatments, the ratio of protein-to-particle in the raw BM reference was
only significantly different from HG. Even though HG decreased the concentration of EVs in
raw milk the most (Table 5-1), the remaining EVs had the highest protein density across all
treatments. A larger number for the protein:particle may result from a greater decrease in particle
number than in protein concentration. And this is consistent with the results obtained for EV
concentration (Figure 5-6), in which the lowest number of particles was observed for HG. The
increase in ratios may also be due to the selective loss of specific EV subsets that have low
protein content, thus decreasing the EV concentration to a greater extent than the protein
concentration. The ratios obtained for UHT and HGUHT decreased when in comparison to raw,
indicating that besides the significant decrease in number of particles (Figure 5-6), there was also
a significant decrease in protein concentration with the severe UHT thermal treatment (143 °C
for 3.3 s). A ratio of 2 x 10-8 µg/particle has been reported in commercially available semiskimmed milk isolated using a similar centrifugation protocol coupled with a precipitating
reagent (Pieters et al., 2015). Somiya et al. (2018) found a ratio of 4.17 x 10-9 µg protein/particle
in store-bought whole BM EVs isolated using a similar method. Ratios reported in literature are
expectedly lower due to the decreased protein content of commercially available, heat processed
and homogenized milk samples. Collectively, the results presented in this study suggest that the
protein:particle ratios may not only be dependent on the concentration of particles, but also on
the integrity of the vesicle membrane to protect the protein content, consistent with previous
evidence (Benmoussa et al., 2016; H. Izumi et al., 2012; Q. Zhou et al., 2012).
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5.4.3.3 miRNA Quantification
Losses of specific milk miRNA (miR-29b and miR-200c) have been reported after
pasteurization, homogenization and microwave heating, and it was proposed that miRNA were
lost due to disruption of exosomal membranes (Howard et al., 2015). The majority of miRNA in
milk is encapsulated in EVs (Baier et al., 2014; Rani, Yenuganti, Shandilya, Onteru, & Singh,
2017; Q. Zhou et al., 2012). In this study, all processing treatments, except LT, resulted in
significant reductions in unadjusted miRNA concentrations when compared to raw samples. The
unadjusted miRNA concentration of BM EV isolations decreased with increasing processing
temperature. Homogenization of pasteurized BM did not significantly reduce unadjusted miRNA
concentration when compared to pasteurization alone. Substantial reductions in the concentration
of small RNA in milk have been evidenced when comparing fractions of raw milk to pasteurized
and to homogenized and pasteurized milk samples (Kleinjan et al., 2021). Significant reductions
in miRNA read counts have also been identified in high heat-treated milk (boiled, extended
shelf-life, and UHT) (Kirchner et al., 2016). Very low amounts of miRNA have been detected in
UHT samples (Kleinjan et al., 2021). Interestingly, similar miRNA profile expressions have been
found in unpasteurized and pasteurized bovine milk, but losses of miRNA-148a-3p in
pasteurization have been detected, in accordance with previous literature (Golan-Gerstl et al.,
2017; Kirchner et al., 2016). Future studies in this area would benefit from focus on the effects of
processing on specific bioactive miRNA sequences with known functional consequences.
In the present study, homogenization caused a greater reduction in the unadjusted
miRNA concentration of the mildly heat-treated sample (LT) than in HTST and UHT. Studies
evaluating the total RNA concentration of raw bovine milk EVs — not only miRNA — found a
yield of 46.33 ng/µL, and decreased RNA content in homogenized milk (17.77 ng/µL), HTST
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treated milk (14.57 ng/µL), and UHT treated milk (12.00 ng/µL) (Kirchner et al., 2016). Zhao et
al. (2018) reported a total RNA concentration of 23.69 ng/µL in raw milk, which was reduced to
20.56, 9.89, and 12.09 ng/µL in defatted, microwaved, and milk treated with a detergent solution
respectively. Ultrasonication also led to a depletion of RNA in exosomes (Leiferman et al.,
2018). Furthermore, miRNA were not detectable in infant formulas (Leiferman, Shu,
Upadhyaya, Cui, & Zempleni, 2019). Although it has been proposed that milk miRNA are not
degraded in the infant gastrointestinal tract for being packaged in membrane (H. Izumi et al.,
2012), disruption of EVs during industrial processing of bovine milk results in decreased
concentrations of miRNA.
A strong correlation (r = 0.91) was identified between unadjusted BM EV protein and
unadjusted BM EV miRNA concentrations across treatments, suggesting the stability of these
cargos may be related to a common factor, such as EV membrane integrity. The miRNA:particle
ratio increased when comparing raw to LT, HG, HTST, and HGHTST (all p > 0.05), yet it was
only significant for HG (p = 0.05). A larger number for the miRNA:particle may result from a
greater decrease in particle number than in miRNA concentration. And this agrees with the
results obtained for EV concentration (Figure 5-6), in which the lowest number of particles was
observed for HG. The increase in ratios may also be due to the selective loss of specific EV
subsets that have low miRNA content, thus decreasing the EV concentration to a greater extent
than the miRNA concentration. The miRNA:particle ratios obtained for UHT and HGUHT
decreased when in comparison to raw, indicating that besides the significant decrease in number
of particles (Figure 5-6), there was also a significant decrease in miRNA concentration with the
severe UHT thermal treatment (143 °C for 3.3 s). Collectively, these results suggest that the
miRNA:particle ratios are related to the integrity of the vesicle membrane to protect the miRNA
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content, consistent with previous evidence (Benmoussa et al., 2016; H. Izumi et al., 2012; Q.
Zhou et al., 2012).
5.5

Conclusion
Raw BM EV content and composition undergoes significant changes when subject to the

unit operations inherent to commercial milk processing, notably homogenization and
pasteurization (HTST and UHT). All treatments caused significant losses of EVs compared to
the raw BM reference, and the greatest loss in HG reflected on significant increases in
protein:particle and miRNA:particle ratios between raw and HG. Processing treatments may
select for specific population subsets of EVs, as the raw BM reference average diameter was
larger than all treatments, except for HGUHT, which was 1.16-fold larger than raw. Nonetheless,
it cannot be excluded that the increase is due to the co-isolation of non-EV particles resulting
from milk processing. The unadjusted protein and miRNA concentrations of total BM EV
isolations reduced with increasing temperature treatment, corroborating previous studies that
suggested commercial processing of bovine milk, especially severe heat treatments, affected the
integrity of the EV membrane, exposing proteins and miRNAs, and reducing their
concentrations. This study contributes foundational knowledge on the effects of processing on
raw BM EVs. Future research may build on these findings to preserve the bioactive compounds
in processed BM products, including infant formula, by narrowing the compositional gap with
human milk. Furthermore, preserving EVs in pasteurized human milk in milk banks may be of
interest to ensure valuable health outcomes for newborns.
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6

EXTRACELLULAR VESICLES IN RAW AND PROCESSED BOVINE MILK:
GENERAL DISCUSSION, CONCLUSIONS AND FUTURE WORK

6.1

General Discussion
EVs are bioactive compounds in bovine and human milks that play roles in human health

and infant development (Alsaweed et al., 2016; Baier et al., 2014). As the knowledge on BM
EVs continues to expand, the ISEV recently released guidelines for the MISEV (Théry et al.,
2018). Although human milk EVs have been characterized in accordance with the MISEV
criteria (Bickmore & Miklavcic, 2020), evidence was lacking for the verification of raw BM EV
isolation. This study also provides evidence to fill a gap in knowledge regarding the impacts of
industrial processing treatments (homogenization, pasteurization) on the content and composition
of BM EVs. Particularly, by controlling processing parameters as part of this design of
experiment and through a comparison of the same milk starting materials for the isolation, using
a standard protocol, of raw and processed BM EVs. Initially, raw BM EVs were characterized in
accordance with the MISEV guidelines to serve as a reference (Chapter 4). Then, raw BM was
processed, EVs were isolated, and the content (concentration, diameter) and composition (protein
and miRNA concentrations) were assessed relative to the raw BM reference (Chapter 5).
The unit operations utilized in the dairy industry to process raw BM to the end-product
that is commercialized is not typically disclosed by manufacturers and may vary widely. For
example, pasteurization may be performed not only through the UHT and HTST techniques
performed in this study, but also at low-temperature low-time (or the ‘Holder’ process) or
higher-heat shorter-time treatments (or ‘flash pasteurization’) (Fellows, 2017). Because these
techniques were not evaluated in the present study, it cannot be inferred that the results found in
this research apply to all processed BM. Similarly, homogenization technologies – equipment
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and pressures – may vary for different manufacturers and products. The effects of these
additional industrial processing treatments on BM EVs warrant further investigations.
When compared to the raw BM reference, the EV concentration was significantly lower
across all treatments, and the greatest decrease in EV concentration resulted from preheated
homogenization alone. It has been suggested in literature that pasteurization does not affect the
number of EVs in raw BM (Kleinjan et al., 2021). Such discrepancy may be attributed to the fact
that previous investigations explored the effects of processing by comparing raw milk obtained
from dairy suppliers to store-bought, commercially processed milk (under unknown conditions).
Comparing EVs isolated from milks from different sources may introduce uncontrolled variables
to a study. Raw BM EVs showed a heterogeneous population even within a single sample, and
this is further enhanced when EVs are derived from unknown bovine species in varying lactation
periods, consuming different feed, stored in different conditions, and isolated using different
protocols (Kleinjan et al., 2021; Quan et al., 2019).
Industrial processing treatments may select for different population subsets of EVs. All
industrial processing treatments resulted in reductions on the average diameter of particles
relative to the raw BM reference, except for HGUHT. This exception may be due to the coisolation of non-EV particles from the severe heat treatment in combination with
homogenization. When adjusted to the concentration of EVs, the protein and miRNA
concentrations were significantly higher only in the preheated homogenization group. This
observation is in accordance with previous literature and suggests a relation between the integrity
of BM EVs and the protein or macromolecular composition of the vesicle membrane
(Benmoussa et al., 2016; H. Izumi et al., 2012; Q. Zhou et al., 2012). This research provides
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foundational knowledge on raw bovine milk EVs and on the impacts of processing to the content
and composition of these vesicles.
6.2

Future Work
This research detailed the content and composition of BM EVs after industrial treatment,

notably preheated homogenization, and pasteurization. BM EVs were isolated using a
differential centrifugation method adapted from literature. The isolation method required
modifications depending on the industrial processing applied to milk samples. Therefore, further
experimental investigations are needed for the optimization of methods for the isolation of EVs
from both raw and processed milk samples. Additionally, defining purity of BM EV isolations
may be beneficial, since isolation methodologies vary, and the BM food matrix is complex.
Industrial processing of raw BM causes significant changes to the milk matrix and the formation
of, for example, protein aggregates and lipid-protein complexes. Such particles may pellet with
EVs during isolation procedures, affecting the purity of the isolated vesicles, and therefore
further investigations on the characterization of these may benefit processed EV isolation
methods.
It was found that the concentration of EVs in raw BM is reduced by industrial processing
treatments. The assessment of average diameter from raw and processed milk samples, as well as
the protein:particle and miRNA:particle ratios, suggested that heat and homogenization
treatments may reduce specific populations of EVs in BM. Future dose-response studies can
inform how temperature affects EV content and composition, and specific EV populations.
Furthermore, new methods could be developed to ensure microbiological safety and the
preservation of EVs, providing input for possible innovations in dairy processing. The concept of
minimal processing and the development of new non-thermal or alternative technologies has
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been deemed necessary in the food industry (Korhonen, 2002). Interdisciplinary studies on the
impact of processing parameters to the nutritional value of milk represent a promising avenue for
future research (Michalski & Januel, 2006). In addition, future studies may develop techniques
for the isolation of EVs from raw BM or for the large-scale production of these bioactive
compounds. Potential exists for EVs to become ingredients for the fortification of dairy or other
food products in the future. Such innovations could be especially useful for improving BM-based
infant formulas to better mimic human milk. Lastly, future studies may as well address the
bioavailability of EVs in infant formula and their outcomes in infant nutrition.
6.3

Conclusion
This is one of the first studies to report the effects of industrial processing on raw BM EVs.

The content and composition of raw and processed BM EVs presented in this research provide
knowledge for future investigations on BM and other food EVs. Further research is needed to
elucidate whether the industrial processing treatments are directly altering the raw BM EV
content and composition, if specific populations of EVs are being selected for or against, or if
there are compositional macromolecular rearrangements of EVs with other components of the
BM food matrix. The foundational information presented may also allow a comparison of EVs
from different mammals. Importantly, understanding the effects of processing on EVs may
contribute to narrowing the compositional gap between human milk and infant formula, ensuring
infants reliant on formulas can obtain bioactive compounds initially present in bovine milk
through improved processing methods and unit operations.
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